Document:

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS
    OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED
    WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION.

 

 

Exhibit 10.50

 

PRIVILEGED AND CONFIDENTIAL

 

 

PARTNERSHIP AGREEMENT

 

BY AND BETWEEN

 

GINKGO BIOWORKS, INC.

 

AND

 

AMYRIS, INC.

 

    

     

    

 

PARTNERSHIP AGREEMENT

 

THIS PARTNERSHIP AGREEMENT (the “Agreement”)
is entered into as of October 20, 2017 (the “Effective Date”) by and between Ginkgo Bioworks, Inc., a Delaware
corporation having its principal office at 27 Drydock Avenue, 8th Floor, Boston, MA 02210 (“Ginkgo”), and Amyris,
Inc., a Delaware corporation having its principal office at 5885 Hollis Street, Ste. 100, Emeryville, CA 94608 (“Amyris”).
Ginkgo and Amyris may be referred to in this Agreement individually as a “Party” and, collectively, as the
“Parties”.

 

RECITALS

 

WHEREAS, Ginkgo and Amyris previously
entered into an Initial Strategic Partnership Agreement, dated June 28, 2016 (the “ISPA”), and subsequently, a Collaboration
Agreement dated September 12, 2016 (the “Collaboration Agreement”), as amended from time to time thereafter; and

 

WHEREAS, Ginkgo and Amyris now wish to
redefine the Parties’ relationship which shall begin to be governed as of the Effective Date by this Partnership Agreement.

 

NOW, THEREFORE, in consideration of the
respective representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE I. DEFINITIONS

 

When used in this Agreement, each of the
following terms shall have the meanings set forth in this Article I:

 

“Action” means any
claim, audit, examination, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at
law or in equity, whether civil or criminal), assessment, arbitration, mediation, investigation, hearing, charge, complaint, demand,
notice or proceeding.

 

“Accounting Principles”
means GAAP, to the extent applicable.

 

“Actual Cost of Goods Sold”
means, with respect to a Product, the cost of goods sold as determined using the Accounting Principles.

 

“Affiliate” means,
as to a Person, any entity which, directly or indirectly, controls, is controlled by, or is under common control with such Person.
For the purposes of this definition, “control” refers to any of the following: (a) direct or indirect ownership of
fifty percent (50%) or more of the voting securities entitled to vote for the election of directors or managers in the case of
a corporation or limited liability company, or of fifty percent (50%) or more of the equity interest with the power to direct
management in the case of any other type of legal entity; (b) status as a general partner in any partnership; or (c) any other
arrangement where an entity possesses, directly or indirectly, the power to direct the management or policies of another entity,
whether through ownership of voting securities, by contract or otherwise.

 

    -1-

     

    

“Amyris Retained Intellectual
Property” means any Intellectual Property associated with the materials transferred by Amyris to Ginkgo and listed on
Exhibit X, including any associated knowhow and/or documentation (such as SOPs) transferred prior to the Effective Date. For clarity,
“associated” means, solely with regards to patents and patent applications within Intellectual Property, such patents
and patent applications that claim materials listed on Exhibit X.

 

“Amyris Transferred Intellectual
Property” means (a) any Intellectual Property associated with the materials transferred by Amyris to Ginkgo and listed
on Exhibit Y, including any associated know-how and/or documentation (such as SOPs) transferred prior to the Effective Date; (b)
any Intellectual Property transferred by Amyris to Ginkgo prior to the Effective Date that comprises Foundry IP or Overlapping
Process IP; and (c) any Intellectual Property developed on or after the effective date of the Collaboration Agreement and prior
to the Effective Date that comprises jointly-owned Foreground IP. For clarity, “associated” means, solely with regards
to patents and patent applications within Intellectual Property, such patents and patent applications that claim materials transferred
by Amyris to Ginkgo and listed on Exhibit Y.

 

Solely for the purposes of this definition
of Amyris Transferred Intellectual Property, Foundry IP, Foreground IP, Non-Collaboration IP and Overlapping Process IP are defined
as follows:

 

(1) “Foundry IP” means any
and all information and inventions conceived and reduced to practice from the effective date of the ISPA to the Effective Date,
which information or inventions relate to the design and genetic engineering, measurement or analysis of microbial host cells,
and all Intellectual Property rights therein or pertaining thereto and excludes [*]

 

(2) “Foreground IP” means,
with respect to a given Party, any and all information and inventions, and all Intellectual Property rights therein or pertaining
thereto, including all Intellectual Property in the Strains and the Products, that have been or are conceived, discovered, developed
or otherwise made or obtained by or on behalf of either Party or its Affiliates or jointly by or on behalf of the Parties or their
Affiliates in the performance of any activities under the Collaboration Agreement, from the effective date of the ISPA to the
Effective Date, and Controlled by either Party or its Affiliates, and, in each case, all Intellectual Property rights therein
or pertaining thereto, and excludes Foundry Intellectual Property (that is not Overlapping Process Intellectual Property), and
Non-Collaboration Intellectual Property;

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -2-

     

    

(3) “Non-Collaboration Intellectual
Property” means, with respect to a Party, any Intellectual Property Controlled by a Party and created (whether as of or
following the effective date of the Collaboration Agreement to the Effective Date) outside the scope of the Collaboration Agreement;

 

(4) “Overlapping Process IP”
means [*]

 

“Applicable Rate” means
a rate equal to the lower of: (a) the Highest Lawful Rate; and (b) ten and one half of one percent (10.5%) per annum.

 

“Average Selling Price”
means, with respect to a Product sold by a Party, the aggregate net sales price per unit (such as a kilogram) of said Product
for all items, instances, or increments of such Product by all customers of the Party, excluding any Incentive Payments related
to such Product. Average Selling Price shall be calculated in accordance with the Accounting Principles.

 

“Business Day” means
a day other than a Saturday or Sunday or other day on which banking institutions located in New York, New York, USA are authorized
or obligated by law or executive order to close.

 

“Calendar Quarter”
means a calendar quarter ending on the last day of March, June, September or December.

 

“Calendar Year” means
a period of time commencing on January 1 and ending on the following December 31.

 

“Change in Control”
means, with respect to a Party, an event in which: (a) any Third Party not then beneficially owning more than fifty percent (50%)
of the voting power of the outstanding securities of such Party acquires or otherwise becomes the beneficial owner of securities
of such Party representing more than fifty percent (50%) of the voting power of the then-outstanding securities of such Party
with respect to the election of the board of directors, board of managers or similar governing body; or (b) such Party consummates
a merger, consolidation or similar transaction with a Third Party where the voting securities of such Party outstanding immediately
preceding such transaction represent less than fifty percent (50%) of the voting power of such Party or surviving entity, as the
case may be, immediately following such transaction; or (c) such Party sells all or substantially all of its assets relating to
this Agreement to a Third Party.

 

“Background Intellectual Property”
means, with respect to a given Party (i) any and all information and inventions, and all Intellectual Property rights therein
or pertaining thereto, including all Intellectual Property in the Strains, that are in existence and Controlled by such Party
or its Affiliates as of the Effective Date, excluding Amyris Transferred Intellectual Property, Amyris Retained Intellectual Property,
and Ginkgo Transferred Intellectual Property.

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -3-

     

    

“Competitor” means:
[*], and any and all of their respective subsidiaries and Affiliates; provided, however, that Amyris or Ginkgo may mutually agree
in writing to update this definition not more than once in any consecutive 12-month period to include any other Third Parties that
compete with any material portion of Ginkgo or Amyris business.

 

“Control” of Intellectual
Property means: (a) solely with regard to Amyris Transferred Intellectual Property, that the applicable party has the rights necessary
to grant the rights and licenses granted or to be granted in this Agreement, whether by ownership or otherwise, without breaching
any Third Party obligation included in an agreement (and an amendment to such agreement if such amendment entered into on or before
the effective date of the Collaboration Agreement and was provided to Ginkgo) set forth on Exhibit C, which may be updated from
time to time by agreement of the Parties; and (b) with regard to Background Intellectual Property and Ginkgo Transferred Intellectual
Property, that the applicable party has the rights necessary to grant the rights and licenses granted or to be granted in this
Agreement, whether by ownership or otherwise. For avoidance of doubt, the Parties agree that Exhibit C includes all agreements
as of the effective date of the Collaboration Agreement, and three additional agreements named therein and effective prior to
the Effective Date, that contain a Third Party obligation that would restrict any grant of rights to Amyris Transferred Intellectual
Property licensed hereunder. To the extent that any license granted under this Section would breach any Third Party obligation
included in an agreement set forth in Exhibit C, such as the grant of an exclusively licensed field to a Third Party, such license
is not hereby granted solely to the extent necessary to avoid such a breach.

 

“Customer Agreement”
means an agreement between one or more of the Parties and a Third Party for the development, manufacture, and/or commercialization
of a product.

 

“Excluded Product(s)”
means any compound(s) or other substance(s) developed, manufactured, and/or commercialized by either Party that is not [*], and
that is outside the scope of this Agreement and not subject to any payments to the other Party for their development, manufacture
or commercialization.

 

“Field” means [*].

 

“Force Majeure Event”
means, with respect to a Party, an event, act, occurrence, condition or state of facts, in each case outside the reasonable control
of such Party (which may include acts of God, acts of any government, any rules, regulations or orders issued by any governmental
authority or by any officer, department, agency or instrumentality thereof, fire, storm, flood, earthquake, accident, war, rebellion,
insurrection, riot, terrorism and invasion) that interferes with the normal business operations of such Party.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -4-

     

    

“GAAP” means U.S. generally
accepted accounting principles, consistently applied between years in the normal course of business.

 

“Ginkgo Transferred Intellectual
Property” means any Intellectual Property associated with the materials transferred by Ginkgo to Amyris and listed on
Exhibit Z, including any associated know-how and/or documentation (such as SOPs) transferred prior to the Effective Date. For
clarity, “associated” means, solely with regards to patents and patent applications within Intellectual Property,
such patents and patent applications that claim materials listed on Exhibit Z.

 

“[*]Program” means the
program to develop, manufacture, commercialize and/or sell [*]for [*] as provided in Exhibit A.

 

“Governmental Entity”
means any instrumentality, subdivision, court, administrative agency, commission, official or other authority of any country,
state, province, prefect, municipality, locality or other government or political subdivision thereof, or any quasi-governmental,
private body or arbitral body exercising any executive, legislative, judicial, quasi-judicial, regulatory, taxing, importing,
administrative or other governmental or quasi-governmental authority.

 

“Highest Lawful Rate”
means the maximum non-usurious rate of interest, as in effect from time to time, which may be charged, contracted for, reserved,
received or collected by Ginkgo in connection with this Termination Agreement under applicable law.

 

"Improvements" means
any enhancement, modification, variation or improvement relating to or arising from existing Intellectual Property.

 

“Incentive Payments”
means any fees and/or milestone payments under a Customer Agreement.

 

“Independent Accounting Firm”
means an independent certified public accounting firm that is one of the six (6) largest, by revenue, accounting firms in the
United States and is approved by both Parties (such approval not to be unreasonably withheld).

 

“Intellectual Property”
means any and all rights in data, discoveries, goodwill, information and inventions, specifically including each of copyright,
know-how, patent, and trade secret rights and any documents or materials that may embody, incorporate, or utilize them.

 

“Law” means any law,
statute, common law, rule, regulation, ordinance, code or other pronouncement having the effect of law, of any federal, national,
multinational, state, provincial, county, city or other political subdivision, including, as applicable: (a) good manufacturing
practices, good laboratory practices, good clinical practices and all other rules, regulations and requirements of any applicable
Governmental Entities; (b) the Foreign Corrupt Practices Act of 1977, as amended, or any comparable laws in any country; (c) the
Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended; and (d) all export control laws.

 

“Loss” means any and
all losses, liabilities, damages, settlements, penalties, fines, costs and expenses (including reasonable attorneys’ fees
and other expenses of litigation) incurred by a Ginkgo Indemnified Party or an Amyris Indemnified Party, as applicable, to the
extent resulting from or arising out of or in connection with any Action brought by a Third Party.

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -5-

     

    

“Net Profits” means,
with respect to a Product, the number of units of Product sold multiplied by the difference between the (a) the Average Selling
Price for such Product and (b) the product of (i) [*] and (ii) the Actual Cost of Goods Sold for such Product. Net Profits shall
be calculated in accordance with the Accounting Principles. In the event such difference is a negative number, then such Net Profits
shall equal zero.

 

“Obligations” means
Amyris’ obligations to pay when due (i) the Partnership Payments, (ii) any and all interest charges associated therewith,
(iii) the Net Profits, and (v) any other amounts Amyris owes to Ginkgo, now or later, whether under this Agreement, the Promissory
Note, or otherwise.

 

“Patent Filing” includes
any application or patent, whether provisional or nonprovisional, filed and/or granted anywhere in the world.

 

“Patent Lead” is the
Party that has ultimate decision making authority with respect to patent prosecution strategy and is responsible for filing, prosecution,
and maintenance of patents, including any related interference, re-issuance, re-examination, opposition, inter partes review,
or post grant review proceedings.

 

“Payment Default” means
a failure by Amyris to pay any Partnership Payment or any other Obligation within ten (10) Business Days after the due date pursuant
to Section 4.3.

 

“Permitted Subcontractor”
means an Affiliate or a Third Party to which a Party may subcontractportions of the activities allocated to it under the Givaudan
Program or any other Product development plan in accordance with the terms of this Agreement.

 

“Person” means any
natural person, general or limited partnership, corporation, limited liability company, limited liability partnership, firm, association
or organization or other legal entity.

 

“Prior Confidentiality Agreement”
means the Mutual Confidential Disclosure Agreement, dated May 11, 2016, by and between Amyris and Ginkgo, as amended.

 

“Product” means an
ingredient created pursuant to a Customer Agreement.

 

“Promissory Note” means
that certain Promissory Note, dated on October 20, 2017, made by Amyris in favor of Ginkgo (as amended, modified, supplemented
or restated from time to time).

 

“Third Party” means
any Person other than a Party or its Affiliates.

 

[*]

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

    -6-

     

    

Construction. In construing this
Agreement, unless expressly specified otherwise:

 

(a)        references
to Articles, Sections and Exhibits are to articles and sections of, and exhibits to, this Agreement;

 

(b)        except
where the context otherwise requires, use of either gender includes any other gender, and use of the singular includes the plural
and vice versa;

 

(c)        headings
and titles are for convenience only and do not affect the interpretation of this Agreement;

 

(d)        any
list or examples following the word “including”, “include” or “includes” shall be interpreted
without limitation to the generality of the preceding words;

 

(e)        except
where the context otherwise requires, the word “or” is used in the inclusive sense;

 

(f)        the
terms “hereof”, “hereto”, “hereby”, “herein” and “hereunder” and words
of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;

 

(g)        the
term “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends,
and such phrase does not mean simply “if”;

 

(h)        except
where the context otherwise requires, “will” means “shall”;

 

(i)        references
to an agreement or instrument mean such agreement or instrument as from time to time amended, modified or supplemented (subject
to any restrictions on such amendments, supplements or modifications set forth herein);

 

(j)        references
to a Person are also to its successors, heirs and permitted assigns;

 

(k)        except
if Business Days are specified, “day” or “days” refers to calendar days;

 

(l)        if
a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is
to be calculated exclusive of that day or Business Day;

 

(m)        “monthly”
means on a calendar month basis;

 

(n)        “quarter”
or “quarterly” means on a Calendar Quarter basis;

 

(o)        “annual”
or “annually” means on a Calendar Year basis;

 

(p)        “year”
means a three hundred sixty-five (365) day period unless Calendar Year is specified;

 

(q)        references
to a Law include any amendment or modification to such Law and any rules or regulations issued thereunder, whether such amendment
or modification is made, or issuance of such rules or regulations occurs, before or, only with respect to events or developments
occurring or actions taken or conditions existing after the date of such amendment, modification or issuance, after the Effective
Date, but only to the extent such amendment or modification, to the extent it occurs after the date hereof, does not have a retroactive
effect;

 

    -7-

     

    

(r)        all
references to “Dollars” or “$” herein shall mean U.S. Dollars;

 

(s)        a
capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein
shall be interpreted in a correlative manner;

 

(t)        any
definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on
such amendments, supplements or modifications set forth herein); and

 

(u)        each
Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has
participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree
that no presumption will apply against the Party which drafted such terms and provisions.

 

ARTICLE II. INTELLECTUAL PROPERTY

 

2.1        Technology
Transfer. The Parties hereby confirm that, pursuant to the ISPA and the Collaboration Agreement, during the Term of such ISPA
and Collaboration Agreement and prior to the Effective Date: (i) Amyris has provided Ginkgo with access and licenses to certain
Intellectual Property, including the Amyris Transferred Intellectual Property and Amyris Retained Intellectual Property, (ii)
Ginkgo has provided Amyris with access and licenses to certain Intellectual Property, including the Ginkgo Transferred Intellectual
Property, and (iii) the Parties collaborated to develop Intellectual Property under the Collaboration Agreement in furtherance
of activities thereto. Pursuant to Section 9.4 (below), all access and license grants as provided in the ISPA and the Collaboration
Agreement to both Ginkgo and Amyris are hereby terminated in their entirety and replaced and superceded with the access and license
grants of this Agreement, as provided in at least this Section and Exhibit A.

 

2.2        Licenses;
Use of Intellectual Property; Convenant Not To Sue.

 

(a)        Amyris
grants to Ginkgo, as of the effective date of the ISPA, a royalty-free, fully paid-up, sublicensable, non-exclusive, perpetual
(i.e. surviving any termination except as provided for herein in regards to insolvency) license under any of the Amyris
Transferred Intellectual Property that is owned or Controlled by Amyris to make, have made, use, sell, offer to sell and import
any products other than farnesene and/or farnesene derivatives that are chemically produced from farnesene, subject to the requirements
of Section 2.3 (Improvement Inventions). Where Ginkgo becomes insolvent, Ginkgo shall no longer be able to exercise any of the
rights granted in this Section, provided that any sublicenses granted by Ginkgo prior to the date of insolvency shall continue
in force. Additionally, Ginkgo acknowledges that, as provided for in the definition of Control in Article 1, to the extent that
any license granted under this Section would breach any Third Party obligation included in an agreement set forth in Exhibit C,
such as the grant of an exclusively licensed field to a Third Party, such license grant is limited in scope to the extent necessary
to avoid such a breach by Amyris.

 

    -8-

     

    

(b)        Ginkgo
grants to Amyris, as of the effective date of the ISPA, a royalty-free, fully paid-up, sublicensable, non-exclusive, perpetual
(i.e. surviving any termination except as provided for herein in regards to insolvency) license under any of its Ginkgo
Transferred Intellectual Property that is owned or Controlled by Ginkgo to make, have made, use, sell, offer to sell and import
and products, subject to the requirements of Section 2.3 (Improvement Inventions). Where Amyris becomes insolvent, Amyris shall
no longer be able to exercise any of the rights granted in this Section, provided that any sublicenses granted by Amyris prior
to the date of insolvency shall continue in force.

 

(c)        For
any any Intellectual Property not transferred to Ginkgo by Amyris as of the Effective Date that Ginkgo would like access to, a
Request can be made pursuant to the provisions of Article III.

 

(d)        The
Parties hereby covenant that neither Party shall initiate or permit any Affiliates to initiate or assist in any way in the initiation
or prosecution of any action asserting a claim of infringement (“Enforcement”) against the other Party (or its sublicensees,
customers or contractors) to the extent that any such Enforcement is with regard to Intellectual Property licensed to the other
Party (or it sublicensees, customer or contractors) pursuant to this Agreement. To the extent that Intellectual Property subject
to this Section 2.2(e) is sublicensed to a sublicensee, customer or contractor, the licensing Party shall provide the identity
of such sublicensee, customer or contractor to the other Party for the purposes of this Section.

 

2.3       
Improvement Inventions.

 

(a)        Inventorship.
The determination of inventorship for any invention which comprises an Improvement to Amyris Transferred Intellectual Property,
Amyris Retained Intellectual Property, or Ginkgo Transferred Intellectual Property that is not Foreground Intellectual Property
(as defined in Exhibit A), under this Agreement shall be made in accordance with the patent laws of the United States. Should
any dispute arise with respect to determination of inventorship, the Parties shall attempt in good faith to resolve the dispute.
In the event that theParties are unable to resolve such dispute within thirty (30) days after receipt of notice of the dispute,
such dispute will be resolved by independent patent counsel not engaged or regularly employed in the past two (2) years by either
Party and reasonably acceptable to both Parties. The decision of such independent patent counsel will be binding on the Parties.
Expenses of such patent counsel will be shared equally by the Parties. For the avoidance of doubt, nothing in this Agreement shall
change or modify a Party’s ownership of its Intellectual Property that exists as of the Effective Date.

 

(b)        
Ownership and Control. Ownership of Improvements to Amyris Transferred Intellectual Property or Ginkgo Transferred Intellectual
Property that is not Foreground Intellectual Property under this Agreement will be determined according to inventorship. For clarity,
ownership “determined according to inventorship” means that, as between the Parties, any invention made by one or
more inventors from Ginkgo and no inventors from Amyris is and will be owned and Controlled by Ginkgo; any invention made by one
or more inventors from Amyris and no inventors from Ginkgo is and will be owned and Controlled by Amyris; any invention made by
one or more inventors from Ginkgo together with one or more inventors from Amyris is and will be owned jointly by Ginkgo and Amyris.
For clarity, the term “invention” as used in this Section includes any Patent Filing with claims to that invention.

 

 

    -9-

     

    

(c)        Patent
Lead. For any Patent Filing on an Improvement that is not Foreground Intellectual Property, the party that owns the Improvement
is Patent Lead and is solely responsible for all decisions for that Patent Filing. For any Patent Filing on a jointly owned Improvement
that is not Foreground Intellectual Property, as between the Parties, Amyris shall have the first right to file any Patent Filing
as Patent Lead on Improvements relating to or arising from Amyris Transferred Intellectual Property, and Ginkgo shall have the
first right to file any Patent Filing as Patent Lead on Improvements relating to or arising from Ginkgo Transferred Intellectual
Property. Where a Party has the first right to file any Patent Filing as Patent Lead and such Party chooses not to file any Patent
Filing, the other Party shall have the second right to file any Patent Filing on such jointly owned Improvement. Where the other
Party exercises the second right to file, the other Party shall be the sole owner of such Improvement. Any disputes as to which
Party will be designated as the Patent Lead will be resolved by the Parties.

 

(i)        Responsibilities.
The Patent Lead shall be responsible for preparation, filing, prosecution and maintenance of patents, including any related interference,
re-issuance, re-examination, opposition, inter partes review, or post grant review proceedings. Solely in regards to jointly
owned Improvements, the other Party shall be permitted but not obliged to provide input to the Patent Lead on the determination
of whether and where to seek patent protection and shall assist the Patent Lead, and the Patent Lead shall consider any suggestions
timely provided by the other Party in good faith, and shall implement such suggestions or provide a reasonable explanation for
a decision not to implement them. Each Party shall provide the status of Patent Filings for jointly owned Improvements to the
other party on a quarterly basis.

 

(ii)        Costs.
The Patent Lead shall bear all costs associated with the preparation, filing, prosecution and maintenance of patents which arise
in connection with the performance of activities conducted under this Agreement, including any related interference, re-issuance,
re-examination, opposition, inter partes review, or post grant review proceedings unless the Parties determine otherwise.

 

(d)        Enforcement.

 

(i)        Each
Party has the sole and independent right to assert any Improvements that it solely owns or Controls. However, should either Party
become aware of any infringement of any jointly owned Improvements, it will promptly notify the other Party and the Parties will
work together to jointly determine whether the Improvements should be asserted against the particular alleged infringer and develop
an enforcement strategy. The Parties shall thereafter consult and cooperate fully to determine courses of action during the term
of such assertion.

 

(ii)        Whenever
one Party is exercising a right to assert Intellectual Property for a jointly owned Improvement hereunder, the other Party hereby
agrees to be named in, or otherwise join, initiate or perform, any such assertion or Action if necessary for standing or otherwise
to ensure that the asserting Party can effect the assertion. If the other Party should be required to be so named or otherwise
join, initiate or otherwise facilitate an assertion, then the option-holding Party will pay all reasonable costs associated with
such naming, joining or assertion.

    -10-

     

    

 

(iii)        Any
royalties, damage awards, or other payments resulting from any assertion of Intellectual Property for a jointly owned Improvement
hereunder shall first be applied to recover all reasonable costs incurred by the asserting Party in pursuing the assertion or
such costs of both Parties if the other Party is joined to such assertion, and thereafter shall be shared between the Parties
in such amounts as determined by the Parties subject to the guiding principles that (i) to the extent that such royalties, damage
awards or other payments relate to a Product, they shall be shared between the Parties in accordance with the terms herein applicable
to sharing of Net Profits related to such Product; (ii) to the extent that such royalties, damage awards or other payments relate
to products or operations outside the scope of this Agreement or Intellectual Property that is not licensed under this Agreement,
they shall be retained one hundred percent (100%) by the Party owning or Controlling the asserted Intellectual Property or split
50%/50% for a jointly owned Improvement; and (iii) to the extent that such royalties, damage awards or other payments relate to
punitive awards, they shall be retained one hundred percent (100%) by the asserting Party or split 50%/50% if the Intellectual
Property is jointly asserted.

 

(iv)        Each
Party will have the sole right, but not the obligation, at its sole expense, to control the defense of any claim by a Third Party,
including any defenses or counterclaims, that any of such Party’s Controlled Intellectual Property is invalid, unpatentable
or unenforceable. Each Party will have the sole right, but not the obligation, at its sole expense, to control the settlement
and licensing of such Party’s owned or Controlled Intellectual Property.

 

2.4        Sublicensing.
Neither Party may sublicense any rights related to the other Party’s Background Intellectual Property, solely owned Improvements,
or Foreground Intellectual Property (as defined in Exhibit A) that is subject to this Agreement and Controlled by the other Party
without the prior written permission of the other Party, such permission not to be unreasonably withheld. Where such prior written
permission of the other Party for a particular sublicensee and sublicense is given pursuant to this Section 2.4, such sublicensee
shall be a “Permitted Sublicensee”.

 

2.5        No
Payment of Third Party Royalties or Fees. Notwithstanding anything herein to the contrary, none of the sublicenses granted
in this Agreement constitutes a covenant by the granting Party to pay any royalties or other fees that become due to a Third Party
licensor in respect of the practice of such Intellectual Property by the other Party. Unless otherwise agreed by the Parties, each
Party shall be responsible for any such royalty obligations or other fees resulting from its practice of any Intellectual Property
sublicensed to it, including any fees under the licensing agreement between [*].

 

2.6        No
Other Licenses Granted. Other than as expressly provided for in this Agreement, no other licenses to any Intellectual Property,
including implied licenses, are hereby granted between the Parties.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -11-

     

    

2.7        Section
365(n).

 

(a)        All
rights and licenses granted under or pursuant to any section of this Agreement, including all rights to sublicense, are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code (the “Bankruptcy Code”),
licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties shall
retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Each Party agrees that the
other Party, to the extent that it is a licensee of such rights under this Agreement, shall retain and may fully exercise all
of its rights and elections under the Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against one
Party under the Bankruptcy Code, the other Party shall be entitled to a complete duplicate of, or complete access to (as such
other Party deems appropriate), any such Intellectual Property and all embodiments of such Intellectual Property; provided, that
such other Party continues to fulfill its obligations as specified herein in full. Such Intellectual Property and all embodiments
thereof shall be promptly delivered to the other Party (i) upon any such commencement of a bankruptcy proceeding upon written
request therefor by the other Party, unless the Party subject to such bankruptcy proceeding elects to continue to perform all
of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on
behalf of the Party subject to such bankruptcy proceeding, upon written request therefor by the other Party. The foregoing is
without prejudice to any rights that either Party may have arising under the Bankruptcy Code, other applicable Law, or this Agreement.

 

(b)        Nothing
in this Section 2.7 shall be deemed any admission that this Agreement is an executory contract or that this Agreement or any obligation
hereunder is otherwise subject to rejection or disavowal in the bankruptcy, liquidation, reorganization, receivership, assignment
for the benefit of creditors, administration, insolvency, or similar proceeding or circumstance (an “Insolvency Proceeding”)
of any Party (the “Withdrawing Party”), nor any admission that upon any such proceeding or circumstance involving
a Party, or upon any such rejection or disavowal by a Party, the other Party (or any sublicensee thereof) would lose or not be
able to enforce or benefit from any right hereunder (or under any applicable sublicense).

 

(c)        Each
of the Parties agrees and acknowledges, as a licensor of Intellectual Property under this Agreement, in entering this Agreement
and granting the rights it respectively grants under this Agreement, and in its efforts to protect its own valuable Intellectual
Property, it has relied on the particular skills and business qualities of the other Party as recipient of such rights. Such skills
and business qualities include the expected future innovation of the other Party, and the particular market segments addressed
by the other Party in its business. Each of the Parties further agrees and acknowledges that upon the occurrence of any Insolvency
Proceeding, this Agreement is of the type described in Section 365(c)(1) and (e)(2) of the Bankruptcy Code, and under any other
applicable Law, for such reasons.

 

ARTICLE III. OPERATIONS

 

3.1        [*].
The operations of the [*] project to which Ginkgo has previously contributed to shall, as of the Effective Date, begin to be governed
by the terms and conditions of this Agreement, including those as expressly recited in Exhibit A.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -12-

     

    

 

3.2        Service
or License Requests. For a product, including a current or new product under an existing Customer Agreement, or a new product
under a new Customer Agreement for which a Party, in its sole discretion, desires the expertise (“Service”) and/or
access to Intellectual Property of the other Party not already licensed to such Party (“License”), such Party can
utilize the procedure set forth below (“Request Procedure”).

 

(a)        If
a requesting Party (“Requestor”) desires a Service and/or a License from the other Party, the Requester will submit
a written request (“Request”) to the other Party (“Recipient”) identifying the relevant Customer Agreement,
product(s), Service and/or License requested. The Recipient will have thirty (30) days to respond to the Request in writing, except
in the case of a Request for manufacturing Services, in which case the Recipient will have sixty (60) days to respond to the Request
in writing. The response shall indicate whether the Recipient approves the

Request either in whole or in part, where
such approval is not to be unreasonably withheld, and shall either indicate the commercially reasonable fee associated with the
grant of the Request or indicate the general rationale for the denial of the Request (as applicable, in whole or in part). The
Requestor then has thirty (30) days to respond in writing agreeing to the conditions of the Recipient for the grant of any approved
Request, or requesting further information on the denial of any Request.

 

(b)        Upon
approval of the Request, the Parties shall negotiate in good faith the terms and conditions of either an agreement for the requested
Services (“Service Agreement”) and/or for the requested License (“License Agreement”)

 

3.3        Improvements
to Licensed IP. Any License Agreement shall provide, as a condition of the License, that the Requestor receiving such License
(“Licensee”) shall agree to grant to the granting Party (“Licensor”) a non-exclusive, royalty-free, fully
paid-up, sublicensable license to any Improvements to the Intellectual Property that comprises the License. The Licensee shall
also agree, as a condition of the License, to ensure that any agreements with any Third Parties that relate to a product covered
by Intellectual Property that is the subject of the License provide for the full ability to grant the Licensor such a license
to Improvements. The Parties shall negotiate in good faith all other terms and conditions of any License Agreement.

 

3.4        Manufacturing.
Where Services requested by Ginkgo from Amyris include manufacturing, such Request shall include an identification of the product
and provide technical development details for such product, and any subsequent Service Agreement shall be in the form of a Manufacturing
Agreement to be entered into between Amyris and Ginkgo. Any Request for manufacturing Services must be approved at a minimum of
twelve (12) months prior to expected initiation of manufacturing. Amyris will produce up to [*] of any given product annually for
Ginkgo. For any greater requested volumes, Amyris will provide a capital expenditure proposal for Ginkgo to submit to the customer
for approval and funding. The Parties shall negotiate in good faith all other terms and conditions of any Manufacturing Agreement.

 

3.5        Subcontracting.
Except as provided in Section 2.4, either Party may subcontract the performance of any other of its respective activities
under this Agreement or any future agreement for Services; provided that (a) any such subcontract shall be subject to the prior
written approval of the non-subcontracting Party, including with respect to the identity of the subcontractor and the terms of
the subcontracting agreement, with such approval not to be unreasonably withheld, (b) the subcontracting Party will oversee the
performance by its subcontractors of the subcontracted activities in a manner that would be reasonably expected to result in their
timely and successful completion and will remain responsible for the performance of such activities as if such subcontracting
Party were itself performing such activities, and (c) any agreement pursuant to which a Party engages a subcontractor will (i)
be consistent in all material respects with this Agreement and (ii) contain terms obligating such subcontractor to: (A) comply
with the non-disclosure and non-use provisions of this Agreement and (B) provide the nonsubcontracting Party with the same rights
with respect to any Intellectual Property arising from the performance of the subcontracted obligation as the non-subcontracting
Party would have under this Agreement as if such Intellectual Property had arisen from the performance of such obligation by the
subcontracting Party. Where such prior written permission of the other Party for a particular subcontractor and subcontract is
given, such subcontractor shall be a “Permitted Subcontractor”.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -13-

     

    

3.6        Secondees
at Amyris. Pursuant to Section 9.4, the September 30, 2016 Letter Agreement for the secondment of Designated People (as defined
in this Section) to Amyris for the performance of work under the Collaboration Agreement is terminated in its entirety as of the
Effective Date. Ginkgo shall determine whether Ginkgo employees or independent contractors (each a "Designated Person"
and collectively, the "Designated People") that are currently performing work under the Collaboration Agreement on location
at Amyris' offices in Emeryville, California, fulfill the secondment period designated in his/her secondment letter agreement
or terminate it prior to his/her end date. If Ginkgo determines that a Designated Person shall fulfill his/her secondment period,
such Designated Person is subject to the following:

 

(a)        Such
Designated Persons shall continue at Ginkgo's sole cost and expense;

 

(b)        In
regards to general day-to-day activities, each Designated Person shall (i) work under the general direction and guidance of one
or more designated Program or Project Leads and at all times on approved Technical Development Plans or as otherwise directed
by the JSC, (ii) be subject to the general workplace policies and procedures of Amyris, (iii) be in compliance with all existing
agreements, whether Customer Agreements or other agreements and (iv) devote one hundred percent (100%) of work time to such work
under this Agreement. For clarity, Ginkgo retains overall control of such Designated People and if Ginkgo disagrees with Amyris'
decisions on how any such Designated Person is being utilized, the Parties shall negotiate in good faith how such Designated Person
shall be utilized for any ongoing and/or future work assignments under this Agreement while at Amyris;

 

(c)        Each
Designated Person is and shall remain an employee or independent contractor of Ginkgo during the Designated Period (as such term
is defined on Schedule A); provided, that nothing in this Agreement shall affect Ginkgo's rights or obligations with respect to
any Designated Person, including without limitation its rights with respect to termination of employment or contractor status
of any Designated Person. Ginkgo will be solely responsible for paying and will pay all salary, bonus, benefits, travel expenses
or any other similar costs and other payments owed to each Designated Person during the Designated Period. Ginkgo shall reimburse
Amyris for any reasonable employment costs incurred by Amyris associated with any of the Designated People. None of the Designated
People shall be eligible to participate in any of the benefit plans of Amyris;and

 

    -14-

     

    

(d)        Ginkgo
represents that each Designated Person is bound by, an employment agreement, or contractor agreement as the case may be, containing
a legally-enforceable obligation of confidence that is at least as restrictive as the confidentiality provisions in the Collaboration
Agreement with respect to any information provided or received in connection with such Designated Person's work during the Designated
Period. In addition, each Designated Person has signed Amyris' confidentiality agreement with respect to any information provided
or received in connection with such Designated Person's work during the Designated Period.

 

ARTICLE IV. FINANCIAL PROVISIONS

 

4.1        [*].

 

(a)        Incentive
Payments. The Parties agree that in regards to the Incentive Payment received by Amyris under the [*] on or around [*], Ginkgo
is solely entitled to and Amyris shall pay Ginkgo $500,000.00 of such Incentive Payment, which is due and payable under this Agreement.

 

(b)        Net
Profits. Net Profits for [*] will be allocated fifty (50%) percent to each of Amyris and Ginkgo. Amyris shall pay such Net
Profits allocable to Ginkgo on a quarterly basis.

 

(i)        Net
Profits that become due and payable prior to the Partnership Payments Term (as defined in Section 4.3(a) below) below shall not
be allocated and due to Ginkgo until such Net Profits due to Ginkgo in the relevant quarter exceed the sum of the interest payments
due in the same such quarter pursuant to Section 2.1(b) of the Promissory Note.

 

(ii)        Net
Profits that become due and payable during the Partnership Payments Term shall not be allocated and due to Ginkgo until such Net
Profits due to Ginkgo in the relevant quarter exceed the sum of the Partnership Payment due in the same such quarter and the interest
payments due in the same such quarter.

 

(iii)        Where
Net Profits exceed the sum of the Partnership Payment and interest payments due in a particular quarter (“Quarterly Total”),
only the difference between such Net Profits and the Quarterly Total shall become due and payable in such quarter, in addition
to such Quarterly Total.

 

(iv)        Subsequent
to the first quarterly payment made pursuant to this Section 4.1, all sums payable in a particular quarter as Net Profits, Partnership
Payments, and interest payments shall be calculated on an aggregated basis. For example, in the ninth quarterly payment, the Net
Profits, Partnership Payments, and interest payments used for the calculation in this Section shall be the aggregated Net Profits,
aggregated Partnership Payments, and aggregated interest payments for all quarters subsequent to the Effective Date and up to
and including the ninth quarter.

 

(c)        Payments
pursuant to this Section will continue until the development, manufacture, and commercialization of [*] under the [*] are permanently
discontinued.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -15-

     

    

4.2        Service
or License Provided Further to a Granted Request. Any License provided by Recipient pursuant to the Request Procedure will
receive from the Requestor ten (10%) percent of the Net Profit for the sales of any Product that is covered by Intellectual Property
that is the subject of the License. Any Service provided by Recipient pursuant to the Request Procedure will be fee based, such
fee(s) to be as mutually agreed to in writing between the Parties.

 

4.3        Partnership
Payments.

 

(a)        Amyris
shall pay directly to Ginkgo quarterly fees of $793,750.00 (each, a “Partnership Payment” and collectively, the Partnership
Payments”) beginning on December 31, 2018 and continuing on the last day of each calendar quarter thereafter, through and
including September 30, 2022 “Partnership Payments Term”), regardless of whether the Parties terminate this Agreement
pursuant to Section 5.2 (or for any other reason). Ginkgo shall invoice Amyris for such Partnership Payments sixty (60) days prior
to the due date for any such payment.

 

All payments shall be received on the
date due to the address set forth below:

 

Ginkgo Bioworks, Inc.

27 Drydock Ave., Floor 8

Boston, MA 02210

Attn:

 

or at such other address or the attention
of such other Person as specified by prior written notice to Amyris.

 

(b)        Where
the total aggregate amount of payments under Section 4.1(b) and 4.3(a) is greater than $19,000,000 (“Aggregate Margin”)
at the Maturity Date, such Aggregate Margin shall be credited toward the Principal Amount of the Promissory Note, where such credit
does not constitute a Prepayment subject to any Prepayment Notice pursuant to the terms of the Promissory Note.

 

(c)        Where
the Aggregate Margin is greater than $31,000,000 (“Further Margin”) at the Maturity Date, such Further Margin shall
be credited towards any payment of Net Profits to Ginkgo subsequent to the Maturity Date, up to the total amount of such Further
Margin. For clarity, the Net Profits paid to Ginkgo shall be reduced to 0% and the Net Profits paid to Amyris shall be increased
to 100% until the total amount of such Further Margin has been paid to Amyris. The total amount of such Further Margin shall be
met where 50% of the Net Profits received by Amyris during this term equal the Further Margin. Thereafter, the Net Profits received
by both Amyris and Ginkgo shall return to 50% for each Party as pursuant to Section 4.1(b).

 

(d)        Acceleration
upon Event of Default; Default Interest. Immediately upon the occurrence of an Event of Default, all remaining unpaid Partnership
Payments shall immediately become due and payable in full without further notice or demand by Ginkgo, and the Partnership Payments
so accelerated shall accrue interest at a fixed per annum rate equal to the Applicable Rate, which interest shall be payable quarterly,
in arrears, on the basis of a 360-day year for the actual number of days elapsed.

    -16-

     

    

 

(e)        Conditions
Precedent. The parties’ obligations and rights hereunder shall be subject to the satisfaction of all the conditions
precedent set forth below:

 

(i)        Execution
of Promissory Note. Ginkgo shall have received, in form and substance satisfactory to Ginkgo, a fully-executed copy of the
Promissory Note.

 

(f)        Events
of Default. Each of the following events shall constitute an Event of Default hereunder:

 

(i)        Payment
Default. A Payment Default; and

(ii)        Cross-Default.
The occurrence of an Event of Default (as defined in the Promissory Note) under the Promissory Note after the date hereof.

 

4.4        Reporting.
From and after the Effective Date, the Parties shall conduct a quarterly reconciliation (the “Quarterly Payment Report”)
of Net Profits and Actual Cost of Goods Sold, on a Product-by-Product basis:

 

(a)        Within
forty-five (45) days after the filing by Amyris of each Quarterly Report on Form 10-Q with the Securities and Exchange Commission,
and within thirty (30) days after the filing by Amyris of its Annual Report on Form 10-K with the Securities and Exchange Commission,
or, if Amyris is no longer making such filings with the Securities and Exchange Commission, within the applicable amount of time
after such filings would have been made, each Amyris shall submit to the Ginkgo a written report setting forth, as applicable,
actual revenues and expenses included in Net Profits and Actual Cost of Goods Sold for such Product on a customer-by- customer
basis for such Calendar Quarter, including, as applicable:

 

(i)        all
sales in units in Net Profits value received from a Customer during such Calendar Quarter; and

 

(ii)        the
relevant Actual Cost of Goods Sold for such Product incurred by each Party or its Affiliates with respect to such Product during
such Calendar Quarter.

 

(b)        The
Quarterly Payment Report shall set forth in reasonable detail the calculation of Net Profits, Actual Cost of Goods Sold, Withholding
Taxes, the amounts paid by customers to each of Amyris, as applicable in order to ensure compliance with Sections 4.1 and 4.2
and the proper allocation of Withholding Taxes pursuant to Section 4.7.

 

4.5        Payment
Mechanics. Each Customer Agreement shall require that all payments of invoices and purchase orders related to the sale of
a Product issued pursuant to such Customer Agreement shall be paid directly to the Party named in the Customer Agreement. If the
Quarterly Payment Report indicates that the payments a Party received during the applicable Calendar Quarter were greater than
an amount equal to the product of (i) 1.1 and (ii) the applicable Actual Cost of Goods Sold for such Calendar Quarter, such Party
shall treat the excess amount as Net Profits and pay the amount of any such excess payment attributable to the other Party’s
share of Net Profits, by wire transfer of immediately available funds, to the other Party.

 

 

    -17-

     

    

4.6        Audits.
For a period beginning as of the Effective Date and ending on the date that is three (3) years following the final payment of
Net Profits and/or Incentive Payments under this Agreement, each Party shall keep, and shall cause its Affiliates to keep, full,
true and accurate books and records containing all particulars relevant to the calculation of Net Profits, Incentive Payments
and Actual Cost of Goods Sold in sufficient detail to enable the other Party to verify the amounts payable by or to it under this
Agreement. Each Party shall have the right, not more than once during any Calendar Year and at its own expense, to have the books
and records of the other Party and its Affiliates, as applicable, audited by an Independent Accounting Firm. Audits under this
Section shall be conducted at the principal place of business of the financial personnel with responsibility for preparing and
maintaining such records, during normal business hours, upon at least thirty (30) days’ prior written notice, and for the
sole purpose of verifying amounts payable by or to such Party under this Agreement. All information and data reviewed in any audit
conducted under this Section0 shall be used only for the purpose of verifying amounts payable by or to a Party under this Agreement
and shall be treated as Confidential Information of the audited Party subject to the terms of this Agreement. The auditing Party
shall cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with the audited Party and its
Affiliates, as applicable. The accounting firm shall disclose to the auditing Party only whether the calculation of Net Profits,
Incentive Payments and Actual Cost of Goods Sold, and payments hereunder are correct or incorrect and the specific details concerning
any discrepancies. If the audit demonstrates that the payments owed under this Agreement have been understated, the audited Party
shall pay the balance to the auditing Party, which shall be paid together with interest in accordance with Section 4.9. Further,
if the amount of the understatement is greater than five percent (5%) of the amount owed to the auditing Party with respect to
the audited period, then the audited Party shall reimburse the auditing Party for the reasonable out-of-pocket cost of the audit.
If the audit demonstrates that the payments owed under this Agreement have been overstated, the audited Party shall be entitled
to credit such amount against payments due to the auditing Party. All payments owed by or to a Party under this Section shall
be made within forty-five (45) days after the results of the audit are delivered to the Parties.

 

4.7        Tax
Matters. Any amounts payable by a Party (the “Payor”) to the other Party (the “Payee”)
pursuant to this Agreement (each a “Payment”) shall be made without deduction or withholding for taxes except
to the extent that any such deduction or withholding is required by Law in effect at the time of the Payment. In the event that
the Payor is required by applicable Law to deduct, withhold and pay over (collectively, “Withhold”) any tax
(a “Withholding Tax”) from or in respect of such Payment, the Payor shall (a) notify the Payee of such requirement
promptly upon first becoming aware thereof, and in no event less than five (5) days prior to Withholding, (b) Withhold the full
amount of such Withholding Tax to the relevant taxing authority as and when due and (c) pay the net after-Withholding Tax amount
of such Payment to the Payee, together with documentation confirming the amount and fact of the associated Withholding. The amount
of Withholding Tax required to be Withheld in respect of a Payment shall be (i) determined in the good-faith discretion of the
Payor, with due regard to any valid documentation previously provided to the Payor by or for the benefit of the Payee, in form
and substance reasonably satisfactory to the Payor, that supports a reduced rate of Withholding Tax in respect of the Payment,
and (ii) treated for all purposes of this Agreement as having been duly and timely paid by the Payor to or for the benefit of
the Payee. The Parties agree to cooperate in good faith to (x) minimize the amount of any Withholding Tax prior to Withholding,
and (y) permit a Payee to recover any excess Withholding Tax previously Withheld. On the date of execution of this Agreement,
each Party will deliver to the other an accurate and complete Internal Revenue Service Form W-9.

 

    -18-

     

    

4.8        Currency
Exchange. All payments to be made by a Party to the other Party shall be made in Dollars. In the case of Actual Cost of Goods
Sold outside the United States, the average reasonable foreign exchange rates in effect when the transactions occur as recorded
in Amyris’ books and records for monthly external reporting will be used. In the case of any other payments made pursuant
to a Customer Agreement that are not in Dollars, the reasonable exchange rate used when the funds are converted to Dollars shall
be used as the conversion rate.

 

4.9        Late
Payments. Without limiting any other rights or remedies available to a Party hereunder, if the paying Party does not pay any
amount due on or before the due date, the paying Party shall pay to such Party interest on any such amounts from and after the
date such payments are due under this Agreement at a rate per annum equal to the then current “prime rate” in effect
published in The Wall Street Journal, Eastern Edition, plus three hundred (300) basis points, or the maximum applicable
legal rate, if less, calculated on the total number of days payment is delinquent; provided that with respect to any disputed
payments, no interest payment shall be due until such dispute is resolved and the interest which shall be payable thereon shall
be based on the finally-resolved amount of such payment, calculated from the original date on which the disputed payment was due
through the date on which payment is actually made.

 

4.10        General
Payment Provisions. Notwithstanding anything to the contrary in this Agreement, (a) there shall be no double-counting of expenses
or revenue in the calculation of Net Profits, Actual Cost of Goods Sold, and Incentive Payments hereunder, and (b) Net Profits,
Actual Cost of Goods Sold, Incentive Payments, and any components thereof shall be determined from the books and records of the
applicable Party and its Affiliates maintained in accordance with the Accounting Principles.

 

ARTICLE V. TERM AND TERMINATION

 

5.1        Agreement
Term. The term of this Agreement shall commence on the Effective Date and shall continue for two (2) years from the Effective
Date unless terminated pursuant to Sections 5.2(a), 5.2(b), 5.2(c) or 5.2(d) below (the “Initial Term”). The
Agreement shall automatically be extended for successive one (1) year periods (each, a “Renewal Term” and,
collectively with the Initial Term, the “Term”) unless a Party delivers a written notice of non-renewal to
the other Party not less than ninety (90) days prior to a Renewal Term.

 

5.2        Termination.

 

(a)        Termination
by Mutual Agreement. At any time during the Term, the Agreement may be terminated upon the mutual written consent of the Parties.

 

(b)        Termination
for Material Non-Performance. If a Party determines that the other Party is repeatedly unable to perform or meet commitments
under the Givaudan Program, the other Party shall have a right to terminate the Agreement on thirty (30) days’ prior written
notice. Notwithstanding the foregoing, if a Party disputes the termination, then Section 5.2(f) shall apply.

 

    -19-

     

    

(c)        Termination
for Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (the “Breaching
Party”) is in material breach of this Agreement, then the Non-Breaching Party may deliver notice of such breach to the
Breaching Party. To the extent such breach is reasonably capable of being cured, if the Breaching Party fails to cure such breach,
or to initiate such steps as would be considered reasonable to effectively cure such breach (and thereafter diligently pursues
such cure), within thirty (30) days after receipt of such notice of breach, the Non-Breaching Party may terminate this Agreement
upon written notice to the Breaching Party with immediate effect.

 

(d)        Termination
for Change in Control. A Party (the “Changed Party”) shall provide fifteen (15) days’ prior written
notice (a “Change in Control Notice”) of any Change in Control of the Changed Party. The other Party may terminate
this Agreement with immediate effect in its sole and absolute discretion upon written notice given to the Changed Party not later
than ten (10) days after the receipt of such Change in Control Notice.

 

(e)        Termination
for Insolvency. At any time during the Term, if either Party becomes insolvent, as evidenced by a filing under the Bankruptcy
Code, for example, this Agreement will automatically be terminated.

 

(f)        Termination
Disputes. If a Party gives notice of non-performance, notice of breach or notice of termination under Sections 5.2(b) or 5.2(c),
and the other Party disputes whether such notice was proper, then the issue of whether or not such non-performance or breach entitled
the Party providing such notice to terminate this Agreement shall be resolved in accordance with Section 9.2, and the Agreement
shall remain in full force and effect until such dispute is resolved, provided that the dispute resolution process may not continue
longer than thirty (30) business days from the date of such notice. If, as a result of such dispute resolution process it is determined
that the notice of non-performance was proper, then the Breaching Party shall be entitled to an additional cure period of ten
(10) days and such termination shall only be effective if the relevant non-performance is not cured or otherwise addressed in
accordance with this Agreement during such period. If, as a result of such dispute resolution process it is determined that the
notice of breach or notice of termination was proper, the Agreement will be terminated with immediate effect. On the other hand,
if, as a result of the dispute resolution process, it is determined that the notice of non-performance, breach and/or termination
was improper, then no termination shall have occurred or shall occur as a result of such notice and this Agreement shall remain
in full force and effect. At the end of such thirty (30) business day period, the Agreement shall be terminated with immediate
effect absent any determination that the notice of non-performance, breach and/or termination was improper.

 

5.3        Effects
of Termination.

 

(a)        Accrued
Rights and Obligations Unaffected. The other provisions of this Section 5.3 notwithstanding, termination of this Agreement by
either Party for any reason will not affect the rights and obligations of the Parties accrued prior to the date of said termination.

 

(b)        Upon
termination of this Agreement for any reason:

 

    -20-

     

    

(i) Each Party shall
return the other Party’s Confidential Information in accordance with Section 8.3; and

 

(ii) Subject to Section
5.3(d) below, each provision of this Agreement that does not expressly survive termination of this Agreement or extend beyond
the Term shall terminate and be of no further force and effect.

 

(c)        Termination
of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including
the Parties’ ability to receive legal damages and/or equitable relief with respect to any breach of this Agreement, regardless
of whether or not such breach was the reason for the termination.

 

(d)        Surviving
Provisions. Article I (Definitions), Section 2.2 (Licenses to IP), Section 2.3 (Improvement Inventions), Section 2.4 (Sublicensing),
Section 2.5 (No Payment of Third Party Royalties), Section 2.7 (Section 365(n)), Article IV (Financial Provisions), Article VI
(Term and Termination), Article VI (Indemnification), Section 7.6 (Insurance), Article VIII (Confidentiality), and Article IX
(Miscellaneous) shall survive termination or expiration of this Agreement.

 

ARTICLE VI. INDEMNIFICATION; LIMITATION
OF LIABILITY

 

6.1        By
Amyris.

 

(a)        Subject
to Section 6.1(b), Amyris agrees, at Amyris’ cost and expense, to defend, indemnify and hold harmless Ginkgo and its Affiliates,
and their respective directors, officers, employees and agents (the “Ginkgo Indemnified Parties”) from and
against any losses, costs, damages, fees or expenses (“Losses”) arising out of any Action brought by a Third
Party to the extent relating to (i) any breach by Amyris of any of its representations, warranties or obligations pursuant to
this Agreement; (ii) the gross negligence or willful misconduct of Amyris or any of Amyris’ subcontractors in performing
any activity contemplated hereunder; (iii) any infringement by Intellectual Property licensed from Amyris, to the extent that
such infringement is based solely on the practice of the claimed subject matter in such Intellectual Property; or (iv) any Excluded
Products developed, manufactured, or commercialized by Amyris.

 

(b)        In
the event of any such Action against any of the Ginkgo Indemnified Parties by any Third Party, Ginkgo shall promptly notify Amyris
in writing of the Action. Subject to this Article, Amyris shall have the right, exercisable by notice to Ginkgo within thirty
(30) days after receipt of notice from Ginkgo of the Action, to assume direction and control of the Action (including the right
to settle the Action solely for monetary consideration) with counsel selected by Amyris and reasonably acceptable to Ginkgo. The
Ginkgo Indemnified Parties shall cooperate with Amyris and may, at their option and expense, be separately represented in any
such action or proceeding. Amyris shall not be liable for any Action costs or expenses incurred by the Ginkgo Indemnified Parties
without Amyris’ prior written authorization. In addition, Amyris shall not be responsible for the indemnification or defense
of any Ginkgo Indemnified Party to the extent arising from any negligent or intentional acts by any Ginkgo Indemnified Party or
the breach by Ginkgo of any representation, obligation or warranty under this Agreement, or any Actions compromised or settled
without its prior written consent. Notwithstanding the foregoing, Amyris shall not settle an Action brought by a Third Party without
the prior written consent of Ginkgo, if such settlement would impose any monetary obligation on Ginkgo or require Ginkgo to submit
to an injunction.

 

    -21-

     

    

(c)        Notwithstanding
anything to the contrary above, (i) in the event of any such Action against a Ginkgo Indemnified Party brought by a Governmental
Entity or criminal action seeking an injunction against a Ginkgo Indemnified Party, or (ii) in the event Amyris does not assume
direction and control of the Action pursuant to Section 6.1(b), Ginkgo shall have the right to control the Action at Amyris’
expense.

 

6.2        By
Ginkgo.

 

(a)        Subject
to Section 6.2(b), Ginkgo agrees, at Ginkgo’s cost and expense, to defend, indemnify and hold harmless Amyris and its Affiliates
and their respective directors, officers, employees and agents (the “Amyris Indemnified Parties”) from and
against any Losses arising out of any Action brought by a Third Party to the extent relating to (i) any breach by Ginkgo of any
of its representations, warranties or obligations pursuant to this Agreement; (ii) the gross negligence or willful misconduct
of Ginkgo or any of Ginkgo’s subcontractors in performing any activity contemplated hereunder; (iii) any infringement by
Intellectual Property licensed from Ginkgo, to the extent that such infringement is based solely on the practice of the claimed
subject matter in such Intellectual Property; (iv) any Excluded Products developed, manufactured, or commercialized by Ginkgo.

 

(b)        In
the event of any such Action against any of the Amyris Indemnified Parties by any Third Party, Amyris shall promptly notify Ginkgo
in writing of the Action. Subject to this Article, Ginkgo shall have the right, exercisable by notice to Amyris within thirty
(30) days after receipt of notice from Amyris of the Action, to assume direction and control of the Action (including the right
to settle the Action solely for monetary consideration) with counsel selected by Ginkgo and reasonably acceptable to Amyris. The
Amyris Indemnified Parties shall cooperate with Ginkgo and may, at their option and expense, be separately represented in any
such action or proceeding. Ginkgo shall not be liable for any Action costs or expenses incurred by the Amyris Indemnified Parties
without Ginkgo’s prior written authorization. In addition, Ginkgo shall not be responsible for the indemnification or defense
of any Amyris Indemnified Party to the extent arising from any negligent or intentional acts by any Amyris Indemnified Party,
or the breach by Amyris of any representation, obligation or warranty under this Agreement, or any Actions compromised or settled
without its prior written consent. Notwithstanding the foregoing, Ginkgo shall not settle an Action brought by a Third Party without
the prior written consent of Amyris, if such settlement would impose any monetary obligation on Amyris or require Amyris to submit
to an injunction.

 

(c)        Notwithstanding
anything to the contrary above, (i) in the event of any such Action against an Amyris Indemnified Party brought by a Governmental
Entity or a criminal action seeking an injunction against an Amyris Indemnified Party, or (ii) in the event Ginkgo does not assume
direction and control of the Action pursuant to Section 6.2(b), Amyris shall have the right to control the Action.

 

    -22-

     

    

6.3 Shared Claims.
Any Losses arising out of any Action brought by a Third Party involving any actual or alleged death or bodily injury arising out
of or resulting from the development, manufacture or commercialization of any Product, to the extent that such Losses

exceed the amount (if any) covered by
the applicable Party’s product liability insurance, shall be shared equally by the Parties, except to the extent such Losses
arise out of any Action brought by a Third Party based on (a) a Party’s breach of any of its representations, obligations
or warranties under to this Agreement, or (b) the gross negligence or intentional act of a Party, its Affiliates, or their respective
Permitted Subcontractors or Permitted Sublicensees, or any of the respective officers, directors, employees and agents of each
of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement.

 

6.4        Limitation
of Liability. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE VI (INDEMNIFICATION), VIII (CONFIDENTIALITY), OR A PARTY’S
LIABILITY PURSUANT TO ARTICLE VI OR VIII, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE,
MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR, EXCEPT WITH RESPECT TO A BREACH OF SECTION 2.2 (LICENSES TO IP), FOR LOSS OF
PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES, ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER,
WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES OR LOSS.

 

ARTICLE VII. REPRESENTATIONS, WARRANTIES
AND COVENANTS

 

7.1 Representation
of Authority; Consents. Ginkgo and Amyris each represents and warrants, and covenants, as applicable, to the other Party that,
except as set forth on Exhibit C (the Amyris Disclosure Schedules) and Exhibit B (the Ginkgo Disclosure Schedules):

 

(a)        it
has full right, power and authority to enter into this Agreement;

 

(b)        its
board of directors has determined that this business arrangement, and the structure of the resulting partnership, is in the best
interest of such party and its stockholders;

 

(c)        this
Agreement has been duly executed by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable
in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization,
moratorium and other Laws relating to or affecting creditors’ rights generally and by general equitable principles and public
policy constraints (including those pertaining to limitations and/or exclusions of liability, competition Laws, penalties and
jurisdictional issues including conflicts of Laws); and

 

(d)        except
as otherwise contemplated in this Agreement, all necessary consents, approvals and authorizations of all government authorities
and other persons required to be obtained by such Party in connection with the execution, delivery and performance of this Agreement
have been and shall be obtained.

 

7.2 No Conflict.
Each Party represents and warrants to the other Party that, except as set forth on Schedule C.2 of Exhibit C (the Amyris Disclosure
Schedules) and Schedule B.2 of Exhibit B (the Ginkgo Disclosure Schedules), the execution and delivery of this Agreement and the
performance of such Party’s obligations hereunder (a) do not conflict with or violate such Party’s corporate organizational
documents or any requirement of applicable Laws and (b) do not conflict with, violate or breach or constitute a default or require
any consent under, any material oral or written contractual obligation of such Party. Each Party agrees that it shall not grant
any right, license, consent or privilege to any Third Party or otherwise undertake any action that would conflict with the rights
granted to the other Party or with any obligations of such Party set forth in this Agreement.

 

    -23-

     

    

7.3 Intellectual
Property. Each Party represents and warrants to the other Party, solely with regard to such Intellectual Property that it
Controls and has licensed hereunder, as follows:

 

(a)        To
the extent such Party Controls Intellectual Property licensed hereunder, such Party has the legal power to and such Party is not
subject to any agreement which restricts or impairs its ability to convey to the other Party all of the license rights for such
Intellectual Property contemplated hereby;

 

(b)        There
are no pending or, to the knowledge of such Party, contemplated Actions relating to any of such Intellectual Property, nor has
such Party received written communication from any Person threatening the institution of any Action against such Party relating
to any of such Intellectual Property;

 

(c)        Except
as contemplated by this Agreement, all rights of such Party in and to such Intellectual Property will be unaffected by this Agreement
and the other transactions contemplated hereunder;

 

(d)        To
the knowledge of such Party, neither the conduct of its business, nor the use of the technology it is providing pursuant to this
Agreement, interferes with, infringes, violates or misappropriates any rights under any valid and unexpired Intellectual Property
of any other Person;

 

(e)        Such
Party has not received any notice alleging any such interference, infringement, violation or misappropriation with regard to such
Intellectual Property (including any such claim that such Party must license or refrain from using such Intellectual Property);
and

 

(f)        To
the knowledge of such Party, no Third Party has interfered with, infringed, violated or misappropriated, or is currently interfering
with, infringing, violating or misappropriating any rights under such Intellectual Property.

 

7.4        Additional
Representations,Warranties & Covenants

 

Ginkgo hereby represents and warrants
to Amyris, that any materials shipped from Amyris to Ginkgo from September 10, 2017 thru the Effective Date that are not listed
on Exhibit Y (the “Returned Materials”):

 

(a)        do
not conflict with, violate or breach, or constitute a default or require any consent under, any oral or written contractual obligation
of such Party to Amyris, including the Partnership Agreement and/or the Promissory Note;

 

(b)        do
not conflict with or violate any applicable Laws;

 

    -24-

     

    

(c)        have
been returned, and Ginkgo has not retained, reproduced or copied such Returned Materials, or any Amyris Confidential Information
solely relating to the Returned Materials; and

 

(d)        Ginkgo
hereby covenants to Amyris, that it will not retain, reproduce or copy any materials provided to Ginkgo by Amyris on or after
the Effective Date for the Givaudan Program without the express written consent of Amyris.

 

For clarity, the treatment
of Materials under this Section 7.4(c) is independent of and does not impact in any way any licenses to intellectual property
or the licenses to the Materials themselves that may be granted pursuant to this Agreement.

 

7.5        Compliance
with Laws. Each Party represents and warrants to the other Party that such Party is in compliance with all applicable Laws
applicable to it. Each Party shall comply in all material respects with all applicable Laws in connection with the development,
manufacture and commercialization of the Products.

 

7.6        Insurance.
Each Party represents and warrants that it is insured with financially sound and reputable insurance companies, in such amounts,
with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses. Each Party
shall not decrease or materially change its insurance policies for so long as this Agreement is in effect and for a period of
five years thereafter.

 

7.7        Disclaimer
of Warranty. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES AND RENOUNCES
ANY WARRANTY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

7.8        Exclusivity.
Each Party agrees that, during the Term, and for a duration of 3 years thereafter, neither Party will collaborate, work with, or
otherwise engage [*] or any of its Affiliates within the Field. For clarity, during the Term, and for a duration of 3 years thereafter
neither party will license its Intellectual Property to [*] or any of its Affiliates within the Field.

 

ARTICLE VIII. CONFIDENTIALITY

 

8.1        Confidential
Information.

 

(a) In connection
with the performance of their respective obligations under this Agreement, each Party (the “Disclosing Party”)
may, itself or through or its Affiliates, disclose certain Confidential Information to the other Party (the “Recipient”)
or its Affiliates. During the Term and at all times thereafter, the Recipient shall maintain all Confidential Information of the
Disclosing Party in strict confidence and shall not use such Confidential Information for any purpose, except that the Recipient
may disclose or permit the disclosure of any such Confidential Information to its Affiliates and Permitted Sublicensees, or its
or their respective directors, officers, employees, consultants, advisors and agents, and its Permitted Subcontractors, who in
each case are obligated to maintain the confidential nature of such Confidential Information on terms no less stringent than those
of this Article VIII. In addition, the Recipient may use or disclose Confidential Information of the Disclosing Party (i) in exercising
the Recipient’s rights and licenses granted hereunder or to fulfill its obligations and/or duties hereunder; provided
that such disclosure is made to a Person who is obligated to confidentiality and non-use obligations no less rigorous than
those of this Section 8.1 and (ii) subject to Section 8.1(c), in prosecuting or defending an Action, complying with applicable
Law and/or submitting information to tax or other Governmental Entities. For the purposes of this Agreement, “Confidential
Information” shall mean (x) any confidential or proprietary information related to the Products and (y) any confidential
or proprietary information relating to the Disclosing Party’s business, including without limitation trade secrets, processes,
formulae, data and know-how, improvements, inventions, chemical or biological materials, techniques, methods for making compounds,
target compounds, product development plans, marketing plans, strategies, customer lists or other information that has been created,
discovered or developed by the Disclosing Party, or has otherwise become known to the Disclosing Party, or for which proper rights
have been assigned to the Disclosing Party, as well as any other information and materials that are deemed confidential or proprietary
to or by the Disclosing Party (including, without limitation, all information and materials of the Disclosing Party’s customers
and consultants and any other third party), regardless of whether any of the foregoing are marked as “confidential”
or “proprietary” or communicated to the Recipient by the Disclosing Party in oral, written, graphic or electronic
form.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -25-

     

    

(b)        The
obligations of confidentiality and non-use set forth above shall not apply to the extent that the Recipient can demonstrate that
the relevant Confidential Information of the Disclosing Party: (i) was publicly known prior to the time of its disclosure under
this Agreement or the Prior Confidentiality Agreement; (ii) became publicly known after the time of its disclosure under this
Agreement other than through acts or omissions of the Recipient, its Affiliates, potential sublicensees or Permitted Sublicensees
in violation of this Agreement; (iii) is or was disclosed to the Recipient or any of its Affiliates at any time, whether prior
to or after the time of its disclosure under this Agreement or the Prior Confidentiality Agreement, by a Third Party having no
fiduciary relationship with the Disclosing Party or any of its Affiliates and having no obligation of confidentiality with respect
to such Confidential Information; (iv) is independently developed by the Recipient or any of its Affiliates without access to
such Confidential Information as evidenced by written records; or (v) was known by the Recipient or any of its Affiliates at the
time of receipt from the Disclosing Party or any of its Affiliates as documented by the Recipient’s or any of its Affiliates’
records.

 

(c)        In
addition, the Recipient or any of its Affiliates may disclose Confidential Information of the Disclosing Party to the extent necessary
to comply with applicable Laws or a court or administrative order; provided that the Recipient provides to the Disclosing Party
prior written notice of such disclosure, to the extent reasonably possible, and that the Recipient takes all reasonable and lawful
actions to obtain confidential treatment for such disclosure and, to the extent possible, to minimize the extent of such disclosure.

 

(d)        Notwithstanding
the obligations in Section 8.1(a) and 8.1(c), a Party may disclose (and, in connection therewith, use) Confidential Information
of the other Party, if such disclosure:

 

    -26-

     

    

(i)        is
made to Governmental Entities in order to obtain patent rights, in each case on the condition that any application for patent
rights may not be filed by a Party without the other Party’s prior written consent where any Confidential Information of
the other Party is disclosed in such application for patent;

 

(ii)        is
made to its Affiliates, Permitted Sublicensees, agents, consultants or other Third Parties (including service providers) for the
development, manufacture or commercialization of Products as provided hereunder, or in connection with an assignment of this Agreement,
a licensing transaction related to products under this Agreement, a loan, financing or investment, or an acquisition, merger,
consolidation or similar transaction (or for such Persons to determine their interest in performing such activities or entering
into such transactions), in each case on the condition that any Third Parties to whom such disclosures are made agree to be bound
by confidentiality and non-use obligations no less rigorous than those contained in this Agreement; or

 

(iii)        consists
entirely of Confidential Information previously approved by the Disclosing Party for disclosure by the Recipient.

 

(e)        Each
Recipient shall be responsible for any breach of the obligations of this Section 8.1 by any Person to whom such Recipient or its
Affiliate disclosed the Disclosing Party’s Confidential Information as if such breach were made by the Recipient.

 

8.2 Publicity;
Attribution; Terms of this Agreement; Non-Use of Names.

 

(a)        Except
as required by judicial order or applicable Law, or as set forth below, neither Party shall make any press release or public announcement
concerning this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld
or delayed. Such press release and the date of its issuance shall be mutually agreed to by the Parties. The Party preparing any
such public announcement shall provide the other Party with a draft thereof at least ten (10) Business Days prior to the date
on which such Party would like to make the public announcement. Neither Party shall use the name, trademark, trade name or logo
of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without
the prior express written permission of the other Party.

 

(b)        Notwithstanding
the terms of this Article VIIIII, either Party shall be permitted to disclose the existence and terms of this Agreement to the
extent required, based on the advice of such Party’s legal counsel, to comply with applicable Laws, including the rules
and regulations promulgated by the U.S. Securities and Exchange Commission (“SEC”) or any other Governmental
Entity. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 8.2(b),
the Parties will consult with one another on the terms of this Agreement for which confidential treatment will be sought in making
any such disclosure. If a Party wishes to disclose this Agreement or any of the terms hereof in accordance with this Section 8.2(b),
such Party agrees, at its own expense, to seek confidential treatment of the portions of this Agreement or such terms as may be
reasonably requested by the other Party; provided that the disclosing Party shall always be entitled to comply with legal
requirements, including the requirements of the SEC.

 

    -27-

     

    

(c)        Either
Party may also disclose the existence and terms of this Agreement in confidence to its attorneys and advisors, and to potential
acquirors (and their respective professional advisors), in connection with a potential merger, acquisition or reorganization and
to existing and potential investors or lenders of such Party, as a part of their due diligence investigations, or to existing
and potential sublicensees or to Permitted Sublicensees and assignees, or to any other Person described in Section 8.1(d)(ii),
in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and non-use substantially
no less rigorous than the terms contained in this Agreement and to use such information solely for the purpose permitted pursuant
to this Section 8.2(c) or Section 8.1(d)(ii).

 

(d)        For
purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure if the content
of such press release, public announcement or disclosure has previously been made public other than through a breach of this Agreement
by the issuing Party or its Affiliates.

 

8.3 Return of Confidential
Information. Upon the expiration or termination of this Agreement, and except for where a license in Article II to such Confidential
Information survives such expiration or termination, upon request, the Recipient shall return to the Disclosing Party or destroy
all Confidential Information received by the Recipient or any of its Affiliates from the Disclosing Party or any of its Affiliates
(and all copies and reproductions thereof). In addition, the Recipient and its Affiliates shall destroy: (a) any notes, reports
or other documents prepared by the Recipient which contain Confidential Information of the Disclosing Party; and (b) any Confidential
Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise
be returned to the Disclosing Party. Any requested destruction of the Disclosing Party’s Confidential Information shall
be certified in writing to the Disclosing Party by an authorized officer of the Recipient supervising such destruction. Notwithstanding
the foregoing, the Recipient and its Affiliates may retain one copy of the Disclosing Party’s Confidential Information solely
for the purpose of compliance with any applicable law or regulation. Notwithstanding the return or destruction of the Disclosing
Party’s Confidential Information, the Recipient shall continue to be bound by its obligations of confidentiality and other
obligations under this Article VIII.

 

ARTICLE IX. MISCELLANEOUS

 

9.1        Governing
Law. This Agreement (and any Actions arising out of or related thereto or to the transactions contemplated thereby or to the
inducement of any Party to enter therein, whether for breach of contract, tortious conduct or otherwise and whether predicated
on common law, statute or otherwise) shall in all respects be governed by and construed in accordance with the laws of the State
of New York, USA, including all matters of construction, validity and performance, in each case without reference to any conflict
of law rules that might lead to the application of the laws of any other jurisdiction.

 

9.2        Dispute
Resolution. Any Action arising out of or relating to this Agreement that is not subject to Article V shall be settled, if
possible, through good faith negotiations between the Parties. If the Parties are unable to settle such dispute within thirty
(30) days or in accordance with the terms of Article V, as applicable, such Action arising out of or relating to this Agreement,
or the breach thereof, shall be resolved as follows:

 

    -28-

     

    

(a)        Such
Action shall be settled by binding arbitration in Chicago, Illinois in accordance with the then current Commercial Arbitration
Rules of the American Arbitration Association and judgment upon the award rendered may be entered in any court having jurisdiction.
The arbitrator shall have the authority to grant any equitable and legal remedies that would be available in any judicial proceeding
subject to any limits set forth herein.

 

(b)        Such
arbitration shall be conducted by a single, independent arbitrator or, if the Parties are unable to agree on such arbitrator,
each Party shall appoint a single, independent arbitrator who must collectively agree on a Third Party, independent arbitrator
to serve as arbitrator hereunder. For clarity, the arbitrator can be either judicial or non-judicial, depending on the nature
of the dispute (i.e., if the dispute is technical in nature, the Parties may elect to agree upon an arbitrator who possesses
a relevant technical background).

 

(c)        The
arbitrator may rule upon motions to compel or limit discovery and shall have the authority to impose sanctions for discovery abuses,
including reasonable attorneys’ fees and costs, to the extent and upon the grounds available for such in the United States
District Courts for the District in which the arbitration is taking place.

 

(d)        The
decision of the arbitrator (the “Award”) as to any Action (including the validity and amount of any Action)
shall be final, binding, and conclusive upon the Parties. Such Award shall be written and shall be supported by written findings
of facts and conclusions. Within 30 days of issuance of an Award any payment required by the Award shall be made unless before
such date any Party shall commence legal action to vacate or modify the Award.

 

(e)        The
Parties to the arbitration may apply to a court of competent jurisdiction for a temporary restraining order, preliminary injunction
or other interim or conservatory relief, as necessary, including without limitation for breach of Section 7.8 or Article VIIIIII
hereunder, without breach of this arbitration provision and without abridgment of the powers of the arbitrator.

 

(f)        The
Parties agree, and agree to direct the arbitrator, that the arbitration will be kept confidential and that the existence of the
proceeding and any proceedings therein, including without limitation any pleadings, briefs or other documents, any testimony or
other oral submissions and any Award, will not be disclosed beyond the arbitrator or arbitration tribunal, the Parties, their
counsel and any Person (including witnesses, if any) involved in the conduct of the proceeding, except (i) in any legal proceeding
concerning the arbitration, including without limitation any proceeding to compel or to stay arbitration or otherwise in aid of
arbitration, for other relief as described in Section 9.2(e), to vacate, modify or confirm an Award, or to enforce an Award or
any judgment based upon an Award, (ii) to the tax, legal, financial or other professional advisors of such Person who are obligated
to keep such information confidential, or (iii) as may be required by Law.

 

(g)        Each
Party shall pay its own costs and expenses (including counsel fees) of any such arbitration, except as may be awarded by the arbitrator
pursuant to Section 9.2(c) above.

 

    -29-

     

    

9.3 Assignment.
Neither Party may assign its rights and obligations under this Agreement without the prior written consent of the other Party,
except that either Party may make such assignment without the prior written consent of the other Party to an Affiliate (so long
as such Party shall remain jointly and severally liable with such Affiliate with respect to all obligations so assigned). Subject
to a Party’s right to terminate this Agreement in connection with a Change in Control pursuant to Section 5.2(d), any request
for consent to assignment shall not be unreasonably withheld or delayed; provided that consent to an assignment to a Competitor
may be withheld as reasonable. Any purported assignment in contravention of this Section 9.3 shall, at the option of the non-assigning
Party, be null and void and of no effect. No assignment shall release either Party from responsibility for the performance of
any accrued obligation of such Party hereunder. This Agreement shall be binding upon and enforceable against the successor to
or any permitted assignee from either of the Parties.

 

9.4        Entire
Agreement; Amendments. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter
hereof, and all previous agreements, including without limitation the ISPA, Collaboration Agreement, and the Letter Agreements
of October 26, 2016 and May 15, 2017 are hereby terminated in their entirety and replaced with this Agreement. Any amendment or
modification to this Agreement shall be made in writing signed by both Parties.

 

9.5        Notices.
All communications, notices, instructions and consents provided for herein or in connection herewith shall be made in writing
and be sent to the address below and will be (a) given in person, (b) sent by registered or certified mail, return receipt requested,
postage prepaid, or (c) sent by a reputable international overnight courier service. Any such communication, notice, instruction
or consent will be deemed to have been delivered on actual receipt.

 

Notices to Ginkgo
shall be addressed to:

 

Ginkgo Bioworks, Inc.

27 Drydock Avenue, 8th
Floor

Boston, MA 02210

Attention: CEO

Attention: General Counsel

 

and

 

Notices to Amyris
shall be addressed to:

 

Amyris, Inc.

5885 Hollis Street,
Ste. 100

Emeryville, CA 94608

Attention: CEO

Attention: General Counsel

 

provided, however, that if either Party
will have designated a different address by notice to the other Party in accordance with this Section 9.5, then to the last address
so designated.

 

9.6 Force Majeure.
No failure or omission by either Party in the performance of any obligation of this Agreement shall be deemed a breach of this
Agreement or create any liability if the same shall arise from a Force Majeure Event; provided that the Party affected
by such cause promptly notifies the other Party and uses diligent efforts to cure such failure or omission as soon as is practicable
after the occurrence of one or more of the above mentioned causes.

 

    -30-

     

    

9.7        Compliance
with Laws; Anti-Corruption Laws.

 

(a)        Each
Party shall perform its obligations under this Agreement in compliance with all applicable Laws.

 

(b)        Anti-Corruption
Laws.

 

(i)       Compliance
with Anti-Corruption Law. In carrying out their responsibilities and exercising their rights under this Agreement, the Parties
shall, and shall ensure that their Permitted Subcontractors shall, comply with all applicable anti-corruption laws in the countries
where the Parties or such Permitted Subcontractors have their principal or other places of business and where they conduct activities
under this Agreement.

 

(ii)        Certain
Covenants regarding Anti-Corruption. Additionally, each Party represents and warrants to the other Party that neither it nor
any of its directors, employees, agents, Permitted Subcontractors or consultants will directly or indirectly pay or give or promise
to pay or give anything of value to any government official or a foreign public official for purposes of (a) influencing any act
or decision of any such person in his official capacity; (b) inducing such person to do or omit to do any act in violation of
the lawful duty of such official; (c) securing any improper advantage; or (d) inducing such person to use his position to affect
or influence any act or decision of government or any legislative, administrative, public agency or other public body, in all
cases with respect to any activities undertaken relating to this Agreement. Additionally, the Parties will make reasonable efforts
to comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to enable the
other Party to ensure compliance with any applicable anti-corruption laws.

 

(iii)        Breach
of Anti-Corruption Covenants. The Parties agree that a breach of the anti-corruption commitments in this Section 9.7(b) shall
be considered a material breach of this Agreement by the relevant Party and that the other Party may immediately seek all remedies
available under law and equity including termination of this Agreement for Material Breach pursuant to Section 5.2(c) if the covenants
under the anti-corruption commitments in this Section 9.7(b) have been breached by a Party (including by its directors, employees,
agents, Permitted Subcontractors or consultants, as relevant), without owing to the other any damages or indemnification resulting
solely from such termination.

 

9.8        Independent
Contractors. It is understood and agreed that the relationship between the Parties is that of independent contractors and
that nothing in this Agreement shall be construed to create a joint venture or any relationship of employment, agency or partnership
between the Parties to this Agreement. Neither Party is authorized to make any representations, commitments or statements of any
kind on behalf of the other Party or to take any action that would bind the other Party. Furthermore, none of the transactions
contemplated by this Agreement shall be construed as a partnership for any tax purposes. Each Party shall select, employ, pay,
supervise, direct and discharge all of its personnel providing services on behalf of such Party, and each Party shall be solely
responsible for the payment of all wages, bonuses, benefits and any other direct or indirect compensation for such Party’s
personnel, as well as worker’s compensation insurance, employment taxes and other employer liabilities relating to such
personnel.

 

    -31-

     

    

9.9        No
Implied Waivers; Rights Cumulative. No failure on the part of Ginkgo or Amyris to exercise, and no delay by either Party in
exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise,
shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege by such Party or be construed as
a waiver of any breach of this Agreement or as an acquiescence therein by such Party, nor shall any single or partial exercise
of any such right, power, remedy or privilege by a Party preclude any other or further exercise thereof or the exercise of any
other right, power, remedy or privilege.

 

9.10        Severability.
If, under applicable Laws, any provision of this Agreement is invalid or unenforceable, or otherwise directly or indirectly affects
the validity of any other material provision(s) of this Agreement (such invalid or unenforceable provision, a “Severed
Clause”), this Agreement shall endure except for the Severed Clause. The Parties shall consult one another and use good
faith efforts to agree upon a valid and enforceable provision that is a reasonable substitute for the Severed Clause in view of
the intent of this Agreement.

 

9.11        Execution
in Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original,
and all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in AdobeTM
Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures.

 

9.12        No
Third Party Beneficiaries. No Person other than Amyris and Ginkgo (and their respective successors and permitted assignees)
shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.

 

9.13        Performance
by Affiliates. Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder and Affiliates
of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding
obligations of such Party and the Parties shall remain liable hereunder for the prompt payment and performance of all their respective
obligations hereunder.

 

[***Remainder of the Page Intentionally
Left Blank; Signature Page to Follow***]

 

 

    -32-

     

    

 

IN WITNESS WHEREOF, the Parties have executed
this Agreement as of the Effective

Date.

 

	 	AMYRIS, INC. 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	 
	 	 	John Melo
	 	 	Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	GINKGO BIOWORKS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Jason Kelly
	 	 	Jason Kelly
	 	 	Chief Executive Officer

 

 

 

 

    -33-

     

    

 

IN WITNESS WHEREOF, the Parties have executed
this Agreement as of the Effective

Date.

	 	AMYRIS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ John Melo
	 	 	John Melo
	 	 	Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	GINKGO BIOWORKS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	 
	 	 	Jason Kelly
	 	 	Chief Executive Officer

 

 

    -34-

     

    

 

 

EXHIBIT A

 

PROVISIONS APPLICABLE SOLELY TO [*]

 

ARTICLE X. VANILLIN ADDITIONAL DEFINITIONS

 

When used solely in
this Exhibit A, each of the following additional terms shall have the meanings set forth in this Article. Other capitalized terms
shall have the meanings as set forth in this Agreement.

 

10.1 “Background
[*]Intellectual Property” means, with respect to a given Party, any and all information and inventions, and all Intellectual
Property rights therein or pertaining thereto, including all Intellectual Property in the Strains, that are in existence and Controlled
by such Party or its Affiliates prior to the Effective Date and that are necessary, required or actually used in the development,
manufacture and/or commercialization of [*]as provided for in Exhibit A, and excludes Amyris Transferred Intellectual Property,
Amyris Retained Intellectual Property, and Ginkgo Transferred Intellectual Property.

 

10.2 “Executive
Committee” means a committee comprised of the Chief Executive Officers of each of Ginkgo and Amyris (or a senior executive
officer of Ginkgo or Amyris designated by such Chief Executive Officers).

 

10.3 “Foreground
Intellectual Property” means, with respect to a given Party, any and all information and inventions, and all Intellectual
Property rights therein or pertaining thereto, conceived, discovered, developed or otherwise made or obtained by or on behalf
of either Party or its Affiliates or jointly by or on behalf of the Parties or their Affiliates on or after the Effective Date
in the performance of activities under this Exhibit A.

 

10.4 “Non-Collaboration
Intellectual Property” means, with respect to a Party, any Intellectual Property Controlled by a Party and created (whether
as of or following the Effective Date) outside the scope of this Exhibit A; provided that any Intellectual Property of a
Party that such Party has used or voluntarily includes for the development, manufacture and/or commercialization of [*]under this
Exhibit A shall still be included in Non-Collaboration Intellectual Property.

 

10.5 “Strain”
means (a) a genetically modified microbial organism developed by or on behalf of either Party or its Affiliates or jointly by
or on behalf of the Parties or their Affiliates, in each case, in the performance of any activities under this Exhibit A for the
purposes of producing chemical small molecule compounds, or any (b) gene, portion of any gene, promoter, ribosome binding site,
regulator, regulatory element, inducer, regulatory pathway, metabolic pathway, metabolome, proteome, transcriptome, genome, secretion
signal, vector, plasmid, chromosome or other material inside of such genetically modified microbial organism. For the avoidance
of doubt, any materials recited in (b), including genes and enzymes of metabolic pathway, regardless of whether such materials
exist inside or outside of a genetically modified microbial organism, shall be considered Strains.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -35-

     

    

 

ARTICLE XI. [*]INTELLECTUAL PROPERTY

 

11.1 Inventions. The
Parties agree to the following:

 

(a)       
Inventorship. The determination of inventorship for any invention which arises in connection with performance of activities
conducted under this Exhibit A (i.e., Foreground Intellectual Property) shall be made in accordance with the patent laws
of the United States. Should any dispute arise with respect to determination of inventorship, the JSC shall attempt in good faith
to resolve the dispute. In the event that the JSC is unable to resolve such dispute within thirty (30) days after receipt of notice
of the dispute, such dispute will be resolved by independent patent counsel not engaged or regularly employed in the past two
(2) years by either Party and reasonably acceptable to both Parties. The decision of such independent patent counsel will be binding
on the Parties. Expenses of such patent counsel will be shared equally by the Parties. For the avoidance of doubt, nothing in
this Exhibit A shall change or modify a Party’s ownership of its Background Intellectual Property or any of its Foundry
Intellectual Property that exists as ofthe Effective Date.

 

(b)        Ownership
and Control Foreground Intellectual Property. Foreground Intellectual Property, regardless of inventorship, in each case,
is and will be owned and Controlled by Amyris. Ginkgo agrees to assign, and hereby does assign, to Amyris any and all rights in
and to such Foreground Intellectual Property, including any and all rights in any patent filings and/or rights of priority to
such patent filings, that claim such Foreground Intellectual Property.

 

(c)        Patent
Lead. For any Patent Filing which arises in connection with performance of activities conducted under this Exhibit A, Amyris
is Patent Lead for that Patent Filing and shall be responsible for preparation, filing, prosecution and maintenance of patents,
including any related interference, re-issuance, re-examination, opposition, inter partes review, or post grant review
proceedings. Amyris shall bear all costs associated with the preparation, filing, prosecution and maintenance of patents which
arise in connection with the performance of activities conducted under this Exhibit A, including any related interference, re-issuance,
reexamination, opposition, inter partes review, or post grant review proceedings unless the JSC determines otherwise.

 

(d) Enforcement.

 

(i)        Subject
to Section (ii) below, Amyris has an independent right to assert any Foreground Intellectual Property that it solely owns or Controls.

 

(ii)        Whenever
one Party is exercising a right to assert Intellectual Property hereunder, the other Party hereby agrees to be named in, or otherwise
join, initiate or perform, any such assertion or Action if necessary for standing or otherwise to ensure that the asserting Party
can effect the assertion. If the other Party should be required to be so named or otherwise join, initiate or otherwise facilitate
an assertion, then the option-holding Party will pay all reasonable costs associated with such naming, joining or assertion.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -36-

     

    

 

(iii)        Any
royalties, damage awards, or other payments resulting from assertion of Intellectual Property hereunder shall first be applied
to recover all reasonable costs incurred by the asserting Party in pursuing the assertion or such costs of both Parties if the
second Party is joined pursuant to Section 11.1(d)(ii), and thereafter shall be shared between the Parties in such amounts as determined
by the JSC subject to the guiding principles that (i) to the extent that such royalties, damage awards or other payments relate
to [*], they shall be shared between the Parties in accordance with the terms herein applicable to sharing of Net Profits related
to [*]; (ii) to the extent that such royalties, damage awards or other payments relate to products or operations outside the scope
of this Exhibit A or Intellectual Property that is not licensed under this Exhibit A, they shall be retained one hundred percent
(100%) by the Party owning or Controlling the asserted Intellectual Property (or split 50%/50% if the Intellectual Property is
jointly owned or Controlled); and (iii) to the extent that such royalties, damage awards or other payments relate to punitive awards,
they shall be retained one hundred percent (100%) by the asserting Party.

 

(iv)        Each
Party will have the first right, but not the obligation, at its sole expense, to control the defense of any claim by a Third Party,
including any defenses or counterclaims, that any of such Party’s Controlled Intellectual Property is invalid, unpatentable
or unenforceable. Each Party will have the first right, but not the obligation, at its sole expense, to control the settlement
and licensing of such Party’s owned or Controlled Intellectual Property.

 

11.2        Licenses
of IP. Each Party hereby grants to the other Party, as of the Effective Date, a non-exclusive, royalty-free, fully paid-up,
sublicensable (to Permitted Sublicensees as provided in this Agreement) license to its Background Intellectual Property and its
Foreground Intellectual Property, solely for the purpose of allowing such other Party to perform activities under this Exhibit
A. For clarity, the Parties agree and acknowledge that the licenses granted under Section 11.2 of this Exhibit A shall not survive
termination or expiration of this Agreement or the cessation or completion of activities pursuant to this Exhibit A, and that
the procedures of Section 8.3 shall then apply. To the extent that any license granted under this Section would breach any Third
Party obligation, such as the grant of an exclusively licensed field to a Third Party, such license is not hereby granted solely
to the extent necessary to avoid such a breach.

 

ARTICLE XII. [*]GOVERNANCE

 

12.1        Executive
Committee. The Executive Committee shall meet (a) at such times as required by this Exhibit A and (b) within ten (10) days
after the request of a Party for the Executive Committee to hold a meeting. Meetings of the Executive Committee shall be effective
only if at least one (1) representative of each Party is present or participating. The Executive Committee may meet either (i)
in person at either Party’s facilities in the United States or at such locations as the Parties may otherwise agree or (ii)
by audio or video teleconference.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -37-

     

    

12.2        Partnership
Joint Steering Committee.

 

(a)        Establishment.
The Parties shall maintain a four-person partnership steering committee (“JSC”) that will have the responsibilities
set forth in this Article hereof. Amyris appoints, and shall be entitled to remove solely at their discretion, two (2) representatives
to the JSC: (x) and (y) ; and Ginkgo appoints, and shall be entitled to remove solely at their discretion, two (2) representatives
to the JSC: (A) and (B) . Each Party’s representatives and any substitute for a representative shall be bound by the
obligations of confidentiality set forth in this Agreement. The JSC shall be led by a chairperson (the “Chairperson”),
who shall not have any greater authority than any other representative on the JSC, but shall be responsible for the following
activities: (i) calling meetings of the JSC and preparing; (ii) preparing an agenda for each meeting and including any items requested
by a member of the JSC on such agenda; (iii) preparing and issuing minutes of each such meeting within thirty (30) days thereafter;
(iv) ensuring that any decision-making delegated to the JSC is carried out in accordance with this Article XII; and (v) preparing
and circulating an agenda for the upcoming meeting; provided that the Chairperson shall include any agenda items proposed
by the other Party. Each Chairperson shall serve for six (6) month terms and appointment of the Chairperson shall rotate between
the Parties, with Amyris appointing the first Chairperson. Each Party shall be free to change its representatives on notice to
the other Party or to send a substitute representative to any JSC meeting; provided, however, that each Party shall ensure
that at all times during the existence of the JSC, its representatives on the JSC are appropriate in terms of expertise and seniority
for the then-current stage of development, manufacture or commercialization of [*].

 

(b)        Responsibilities.
The JSC shall have responsibility for: (i) ensuring regular communication between the Parties; (ii) ensuring the establishment
of, and monitoring of progress of the [*]Program; (iii) monitoring, reviewing, and reporting on the progress of [*]developed pursuant
to this Exhibit A; and (iv) performing such other functions as expressly set forth in this Exhibit A or appropriate to further
the purposes of this Exhibit A, as mutually agreed upon by the Parties in writing. The JSC has the authority to delegate any of
these responsibilities as it sees fit. Each individual member of the JSC shall be bound by the obligations of confidentiality set
forth in this Agreement. Each individual member of the JSC shall not have any independent authority to act on behalf of the JSC
unless such authority has been delegated to such individual in advance by the JSC.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -38-

     

    

12.3        [*]Program
Management Team; Other Subcommittees. The JSC shall establish a project management team (“Project Management Team”)
for [*] (and, for clarity, the JSC may instead determine that there should be different Project Management Teams for early stage
vs. late stage activities for [*]under the [*]Program, or any other approach approved by the JSC). The JSC shall designate a project
lead (each, a “Project Lead”) from one Party and, if deemed appropriate by the JSC, a co-project lead (the
“Co-Project Lead”) from the other Party for the Project Management Team, who shall be responsible for monitoring
the Project and reporting to the JSC concerning status of the Project and the progress of [*]developed pursuant to this Exhibit
A. The Project Lead and Co-Project Lead shall use good faith efforts to execute the applicable Project in accordance with its
[*]Program. The Project Lead shall be primarily responsible for (a) achieving any milestones under the Project; (b) commercializing
[*]under a given Project at scale; and (c) with reasonable consultation with the Co-Project Lead, developing and overseeing the
Project, including defining tasks, task dependencies and goals that leverage the capabilities of each Party to commercialize [*]under
the Project at scale; provided, the Project Lead shall use commercially reasonable efforts to allocate early stage development
work and later stage scale-up and manufacturing work, in each case, as appropriate based on capabilities and capacity of each
Party with the intention of maximizing speed to market for [*]; and provided, further, that the Party that is a party to
the applicable Customer Agreement shall be solely responsible for interfacing with the customer of the Project (including, without
limitation, serving on any steering or similar committee under the applicable Customer Agreement for the [*]Program). In the event
that there is a dispute concerning the Project between the Project Lead and a Co-Project Lead, the JSC shall attempt to resolve
such dispute in good faith and, if the JSC is unable to do so, such dispute shall be resolved in accordance with Section 12.6.
The JSC may establish and disband such other subcommittees as deemed necessary by the JSC (each, a “Subcommittee”).
For the avoidance of doubt, either Party may designate the same representatives to serve on the Project Management Team (including
as Project Lead and/or Co-Project Lead), or on the JSC. Each Party shall be free to change its representatives on notice to the
other or to send a substitute representative to any Project Management Team; provided, however, that (x) the JSC shall
be required to approve the Project Lead and Co-Project Lead, and (y) each Party shall ensure that at all times during the existence
of any Project Management Team, its representatives on the Project Management Team are appropriate in terms of expertise and seniority
for the then-current stage of the development, manufacture and commercialization of [*]under the Project. Each Party’s representatives
and any substitute for a representative shall be bound by the obligations of confidentiality set forth in this Agreement. No Project
Management Team shall have the authority to bind the Parties hereunder and the Project Management Team shall report to, and any
decisions shall be made by, the JSC.

 

12.4        Committee
Meetings. The JSC and each of the Project Management Teams shall each hold at least one (1) meeting per Calendar Quarter at
such times during such Calendar Quarter as the Chairperson elects to do so. Meetings of the JSC and each of the Project Management
Teams, respectively, shall be effective only if at least one (1) representative of each Party is present or participating. The
JSC and Project Management Team may meet either (a) in person at either Party’s facilities in the United States or at such
locations as the Parties may otherwise agree or (b) by audio or video teleconference; provided that no less than one (1) JSC meeting
during each Calendar Year shall be conducted in person. Other representatives of each Party involved with the relevant Projects
may attend meetings as non-voting participants, subject to the confidentiality provisions set forth in Article VIII. Additional
meetings of the JSC, or Project Management Teams may also be held with the consent of each Party, and neither Party shall unreasonably
withhold its consent to hold such additional meetings, or as required under this Exhibit A. Each Party shall be responsible for
all of its own expenses incurred in connection with participating in all such meetings, and such expenses shall not be included
in the calculation of Actual Cost of Goods Sold hereunder.

 

12.5        Authority.
The JSC and each Project Management Team shall have only the powers assigned expressly to it in this Exhibit A, and shall not
have any power to amend, modify or waive compliance with this Exhibit A. In furtherance thereof, each Party shall retain the rights,
powers and discretion granted to it under this Exhibit A and no such rights, powers or discretion shall be delegated or vested
in the JSC Project Management Team unless such delegation or vesting of rights is expressly provided for in this Exhibit A or
the Parties expressly so agree in writing.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -39-

     

    

12.6        Decisions.

 

(a)        Initial
Dispute Resolution Procedures. Subject to the provisions of this Article XII, actions to be taken by the JSC and each of the
Project Management Teams shall be taken only following a unanimous vote, with each Party (through its representatives) having
one (1) vote. If any Project Management Team fails to reach consensus on a matter before it for decision for a period in excess
of thirty (30) days, either Party shall have the right to refer the matter to the JSC.

\

(b)        Final
Decision-Making. If the JSC fails to reach unanimous agreement on a matter properly before it for decision for a period in
excess of ten (10) days, the matter shall be referred to the Executive Committee. If the Executive Committee fails to reach unanimous
agreement on a matter before it for decision for a period in excess of ten (10) days, the matter shall be resolved in accordance
with Section 9.2.

 

12.7        Conduct
of Meetings; Future Adjustments in Governance.

 

(a)        Any
meetings of the Executive Committee, JSC, or a Project Management Team shall have an agenda circulated in advance of such meeting.
The Party responsible for preparing an agenda for any such meeting shall include on the agenda any items suggested by the representatives
of the other Party to be addressed at such meeting. Minutes will be taken at each meeting by an individual appointed by the applicable
committee, and circulated for review and approval of the same. Copies of all final agendas and approved meeting minutes will be
provided to each Party’s legal counsel.

 

(b)        The
Parties may at any time by mutual written agreement create or delete governance committees or subcommittees or make other modifications
to the governance structures contemplated by this Exhibit A in order to promote the efficient operation of the Projects.

 

    -40-

     

    

EXHIBIT B

 

Ginkgo’s Disclosure Schedules

 

Information contained in any section of
these disclosure schedules shall be deemed to be disclosed for purposes of all other sections of the disclosure schedule to the
extent that the relevance of any such disclosure to any other section of the disclosure schedules is reasonably apparent on the
face of such disclosure.

 

Section B.2

 

For the avoidance of
doubt, it is understood by the Parties that certain provisions of the agreements listed below limit the rights and obligations
of Ginkgo granted pursuant to Article II or Exhibit A of the Agreement.

 

“Control” is limited by the
restrictions set forth in all agreements, each as amended from time-to-time, to which Ginkgo is a party as of the Effective Date,
including without limitation the following:

 

[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    -41-

     

    

[*]

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -42-

     

    

[*]

 

 

Section B.3(a)

 

With respect to section
B.3(a), scheduled exceptions are as follows:

 

Ordinary Course Licenses
and Sublicenses Granted. All licenses and rights granted by Ginkgo under the Agreement and all of Ginkgo’s obligations under
the Agreement are subject to and qualified by the exclusive and/or non-exclusive licenses and the covenants not to compete that
Ginkgo and its affiliates have granted to Third Parties (including the U.S. government in some cases) as of the Effective Date.

 

Section B.3(b)

 

Regarding receipt of
royalty payment

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    -43-

     

    

Ginkgo and/or its
affiliates, in return for the licenses and covenants that Ginkgo and its affiliates have granted to Third Parties as of the Effective
Date, receive compensation in various forms from such Third Parties.

 

Regarding licensing
to commercially exploit any of Ginkgo’s Intellectual Property

 

See Section B.3(a)
and response in B.3(b) regarding receipt of royalty payment

 

Section B.3(c)

 

During the ordinary
course of business, Ginkgo has ongoing examinations, prosecutions, and appeal proceedings for patent and trademark applications
with the U.S. Patent & Trademark Office and foreign counterpart offices or government entities.

 

    -44-

     

    

EXHIBIT C

 

Amyris’ Disclosure Schedules

 

Information contained in any section of
these disclosure schedules shall be deemed to be disclosed for purposes of all other sections of the disclosure schedule to the
extent that the relevance of any such disclosure to any other section of the disclosure schedules is reasonably apparent on the
face of such disclosure.

 

Section C.2

 

For the avoidance of doubt, it is understood
by the Parties that certain provisions of the agreements listed below limit the rights and obligations of Amyris granted pursuant
to Article II or Exhibit A of the Agreement:

 

“Control” is limited by the
restrictions set forth in all agreements to which Amyris is a party as of the effective date of the Collaboration Agreement and
amendments thereto solely if such amendments were entered into on or before the effective date of the Collaboration Agreement
including without limitation the following:

 

[*]

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

    -45-

     

    

[*]

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -46-

     

    

Section C.3(a)

 

[*]

 

Section C.3(b)

 

Regarding payment of royalty

 

[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -47-

     

    

[*]

 

Section C.3(c)

 

[*]

 

Section C.3 (e)

 

[*]

 

Section C.6

 

[*]

    -48-

     

    

[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

    -49-

     

    

[*]

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

    -50-

     

    

[*]

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

    -51-

     

    

EXHIBIT X

 

Amyris Retained Intellectual Property

 

 

 

	
        Strain or plasmid number

         
	 	
        Generation/Transfer Year

         

	[*] 	 	
        [*]

         

	[*]	 	[*]
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

    -52-

     

    

EXHIBIT Y

 

Amyris Transferred Intellectual Property

 

 

 

	
        Strain or plasmid number

         
	 	
        Generation/Transfer Year

         

	[*] 	 	
        [*]

         

	[*] 	 	[*]
	[*] 	 	[*]
	 	 	 
	[*]	 	[*]
	 	 	 
	[*]	 	[*]

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    -53-

     

    

EXHIBIT Z

 

Ginkgo Transferred Intellectual Property

 

	Detailed Description of Transfer	Date of Transfer
	[*]	3/24/17
	[*]	5/31/17
	[*] 	7/14/17

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

 

 

 

 

 

 

 

    -54-

     

    

EXHIBIT ZZ

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

 

 

    	 	-55-	 

     

    

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	-56-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	-57-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-58-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-59-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-60-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-61-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-62-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-63-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-64-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    	 	-65-	 

     

    

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

 

- 66 -Exhibit 10.65

 

EXECUTION VERSION

 

CREDIT AGREEMENT

 

This CREDIT AGREEMENT, dated as of
December 28, 2017 (as amended, modified or supplemented from time to time, this “Agreement”), is entered into
by and between AMYRIS, INC., a Delaware corporation, whose principal place of business is 5885 Hollis Street, Ste. 100,
Emeryville, California 94608 (the “Company”), and DSM Finance BV, a Netherlands private company with
limited liability, whose principal place of business is Het Overloon 1, 6411 TE Heerlen, the Netherlands (the “Lender”
and, together with the Company, the “Parties”).

 

RECITALS

 

A. In connection with the business cooperation
between the Company and the Lender, the Lender has agreed to purchase from the Company, and the Company has agreed to sell to the
Lender, an unsecured note having a principal amount of Twenty-Five Million United States Dollars ($25,000,000) (the “Note).

 

B. Capitalized terms not defined in Section
6 hereof or otherwise defined herein shall have the meaning set forth in the form of Note (as defined below) attached hereto as
Exhibit A.

 

AGREEMENT

 

NOW THEREFORE, in consideration of the foregoing,
and the representations, warranties, and conditions set forth below, the Parties, intending to be legally bound, hereby agree as
follows:

 

		1.	Purchase and Sale of the Note.

 

		(a)	The sale and purchase of the Note shall take place at a closing (the “Closing”), to be held at the offices
of Shearman & Sterling LLP, 535 Mission Street, 25th Floor, San Francisco, CA 94105 on the date hereof as soon as
reasonably practicable following the execution and delivery of this Agreement (the day on which the Closing takes place being
the “Closing Date”). At the Closing, the Company will deliver the Note to the Lender against receipt by the
Company of the principal amount of the Note at the Closing. The Note will be registered in the Lender’s name in the Company’s
records.

 

		(b)	The proceeds of the sale and issuance of the Note shall be used to repay all of the Company’s indebtedness outstanding,
including principal and interest or other amounts due, pursuant to that certain Note, dated December 31, 2016, issued by the Company
to Wutian Supply Chain Corporation Limited pursuant to that certain Credit Agreement, dated October 26, 2016, entered into by and
between the Company and Guanfu Holding Co., Ltd. (such note, the “Guanfu Note”, and such credit agreement, the
“Guanfu Credit Agreement”).

 

 

    

     

    

 

 

		2.	Representations and Warranties of the Company. The Company represents and warrants to the Lender as of the date
hereof and as of the Closing Date that:

 

		(a)	Due Incorporation, Qualification, etc.  Each of the Company and its Subsidiaries (i) is a corporation duly organized,
validly existing and in good standing under the laws of its state of incorporation; (ii) has the power and authority to own, lease
and operate its properties and carry on its business as now conducted; and (iii) is duly qualified, licensed to do business and
in good standing as a foreign corporation in each jurisdiction where the failure to be so qualified or licensed could reasonably
be expected to have a Material Adverse Effect.

 

		(b)	Authority. The execution, delivery and performance by the Company of this Agreement and the Note and the consummation
by the Company of the transactions contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly
authorized by all necessary corporate actions on the part of the Company.

 

		(c)	Enforceability. This Agreement and the Note have been duly executed and delivered by the Company and each of this Agreement
and the Note constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its respective terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

		(d)	Non-Contravention. The execution and delivery by the Company of this Agreement and the Note and the performance and
consummation by the Company of the transactions contemplated hereby and thereby do not and will not (i) violate the certificate
of incorporation or bylaws of the Company or any judgment, order, writ, decree, statute, rule or regulation applicable to the Company;
(ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether
after the giving of notice or lapse of time or both), any mortgage, indenture, agreement, instrument or contract to which the Company
is a party or by which it is bound except to the extent such violation, breach or acceleration could not reasonably be expected
to result in a Material Adverse Effect; or (iii) result in the creation or imposition of any Lien upon any property, asset or revenue
of the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of any permit, license, authorization or approval
applicable to the Company, its business or operations, or any of its assets or properties except to the extent such suspension,
revocation, impairment, forfeiture or nonrenewal could not reasonably be expected to have a Material Adverse Effect.

 

		(e)	Approvals. No consent, approval, order or authorization of, or registration, declaration or filing with, any
                                                                                                     governmental authority or other Person is required in connection with the execution and delivery by the Company of this
                                                                                                     Agreement and the Note and the performance and
consummation by the Company of the transactions contemplated hereby and thereby, except for those already obtained.
 

 

 

    2

     

    

 

		(f)	No Violation or Default. None of the Company or any of its Subsidiaries is in violation of or in default with respect
to (i) its certificate of incorporation or bylaws or any judgment, order, writ, decree, statute, rule or regulation applicable
to such Person; or (ii) any mortgage, indenture, agreement, instrument or contract to which such Person is a party or by which
it is bound (nor is there any waiver in effect which, if not in effect, would result in such a violation or default), where, in
each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected
to have a Material Adverse Effect.

 

		(g)	Litigation. No actions (including, without limitation, derivative actions), suits, proceedings or investigations are
pending or, to the actual knowledge of the Company, threatened against the Company or any of its Subsidiaries at law or in equity
in any court or before any other governmental authority which (i) would reasonably be expected (alone or in the aggregate) to have
a Material Adverse Effect or (ii) seeks to enjoin, either directly or indirectly, the execution, delivery or performance by the
Company of this Agreement and the Note or the transactions contemplated hereby and thereby.

 

		(h)	Properties. Each of the Company and its Subsidiaries owns or leases all such properties, including lands, buildings,
machinery and production equipment, as are necessary to the conduct of its operations as presently conducted. Each of the Company
and its Subsidiaries has good, marketable and legal title to, or a good, marketable and valid leasehold interest in, all of its
material properties and assets, and all such properties are free of any Liens other than as disclosed in the Company’s public
filings. Neither the Company nor any of its Subsidiaries has received any notice of proceedings relating to its properties which,
singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect.

 

		(i)	Labor. No labor problem or dispute with the employees, including management, of the Company or any of its Subsidiaries
exists or is threatened or imminent, except as would not have a Material Adverse Effect.

 

		(j)	Commission Filings. The Company has timely filed (subject to 12b-25 filings with respect to certain periodic filings)
all reports, schedules, forms, statements and other documents required to be filed by it with the U.S. Securities and Exchange
Commission (the “Commission”) pursuant to the reporting requirements of the U.S. Securities Exchange Act of
1934, as amended (the “Exchange Act”) (all of the foregoing filed with the Commission prior to the date hereof
and all financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred
to herein as the “SEC Documents”). As of their respective dates, the SEC Documents complied in all material
respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated
thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the Commission, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

 

    3

     

    

		(k)	Other Regulations. None of the Company or its Subsidiaries is subject to regulation under the U.S. Investment Company
Act of 1940 or to any federal or state statute or regulation limiting its ability to incur indebtedness.

 

		(l)	No Note Registration. The Company is under no obligation to effect any registration of the Note under the U.S. Securities
Act of 1933, as amended (the “Securities Act”), or any state securities laws with respect to the Note or to
file for or comply with any exemption from registration.

 

		(m)	Intellectual Property. The Company and each of its Subsidiaries owns, or is licensed to use, all intellectual property
necessary to conduct its business as currently conducted except for such intellectual property the failure of which to own or license
would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. To the knowledge
of the Company, (a) the conduct and operations of the businesses of the Company and each of its Subsidiaries does not infringe,
misappropriate, dilute or violate any intellectual property owned by any other Person and (b) no other Person has contested any
right, title or interest of the Company or any of its Subsidiaries in, or relating to, any intellectual property, other than, in
each case, as would not, in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

		(n)	Solvency. Except as set forth on Schedule 2(n), on the Closing Date, both before and after giving effect to (a) the
sale and purchase of the Note, (b) the disbursement of the proceeds of the Note to or as directed by the Company, (c) the
consummation of the transactions contemplated to occur on the Closing Date under the Quota Purchase Agreement and (d) the payment
and accrual of all transaction costs in connection with the foregoing, the Company will not be Insolvent.

 

For the purposes of the above clause
(n), “Insolvent” means, with respect to any Person as of any date of determination, that, as of such date, (i)
the present fair saleable value of such Person’s assets is less than the amount required to pay such Person’s total
indebtedness, (ii) such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts
and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it will incur debts that would
be beyond its ability to pay as such debts mature or (iv) such Person has unreasonably small capital with which to conduct the
business in which it is engaged as such business is now conducted and is currently proposed to be conducted.

 

    4

     

    

		(o)	Material Adverse Effect. Since December 31, 2017, there has been no Material Adverse Effect or any event or circumstance
which would reasonably be expected to result in a Material Adverse Effect.

 

		3.	Representations and Warranties of the Lender. The Lender represents and warrants to the Company as of the date
hereof and as of the Closing Date that:

 

		(a)	Binding Obligation. The Lender has full legal capacity, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder. This Agreement and the Note is a valid and binding obligation of the Lender, enforceable
in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting
the enforcement of creditors’ rights generally and general principles of equity.

 

		(b)	Securities Law Compliance. The Lender is purchasing the Note for its own account for investment, not as a nominee or
agent, and not with a view to, or for resale in connection with, the distribution thereof. Lender has received or has had full
access to all of the information necessary and appropriate to make an informed investment decision. The Lender is an accredited
investor as such term is defined in Rule 501 of Regulation D under the Securities Act. The Lender acknowledges that it can bear
the economic risk of the investment in the Note.

 

		(c)	Approvals. No consent, approval, order or authorization of, or registration, declaration or filing with, any governmental
authority or other Person is required in connection with the execution and delivery by the Lender of this Agreement and the performance
and consummation by the Lender of the transactions contemplated hereby and thereby, except for those already obtained.

 

		(d)	Source of Funds. The funds provided by the Lender to the Company in connection with this Agreement and the Note are
in full compliance with the money laundering statutes of all jurisdictions to which the Lender is subject, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency
having jurisdiction over the Lender.

 

		(e)	No Note Registration. The Lender is under no obligation to effect any registration of the Note under the Securities
Act, or any state securities laws with respect to the Note or to file for or comply with any exemption from registration.

 

		4.	Conditions to Obligations of the Lender. The Lender’s obligations at the Closing are subject to the fulfillment,
on or prior to the Closing Date, of all of the following conditions, any of which may be waived in whole or in part by the Lender:

 

		(a)	Representations and Warranties. The representations and warranties made by the Company in Section 2 hereof shall have
been true and correct when made.

 

		(b)	Governmental Approvals and Filings. Except for any notices required or permitted to be filed after the Closing Date
with certain federal and state securities commissions, the Company
shall have obtained all governmental approvals required in connection with the lawful sale and issuance of the Note.

 

 

    5

     

    

 

		(c)	Legal Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the Lender, of the Note
shall be legally permitted by all laws and regulations to which the Lender or the Company is subject.

 

		(d)	Transaction Documents. The Company shall have duly executed and delivered to the Lender this Agreement and the Note.

 

		(e)	No Event of Default. After giving effect to the sale and issuance of the Note and the repayment in full of all outstanding
indebtedness of the Company under the Guanfu Note on the Closing Date, no Event of Default shall exist.

 

		(f)	Other Transactions. All conditions to the closing of the transactions pursuant to the Quota Purchase Agreement, dated
as of November 17, 2017, between the Company, AB Technologies LLC, and DSM Produtos Nutricionais Brasil S.A. (as it may be amended
from time to time in accordance with its terms, the “Quota Purchase Agreement”) (other than those conditions
related to the issuance of the Note) shall have been satisfied or waived by the parties to the Quota Purchase Agreement.

 

		5.	Conditions to Obligations of the Company. The Company’s obligations at the Closing are subject to the fulfillment,
on or prior to the Closing Date, of the following conditions, any of which may be waived in whole or in part by the Company:

 

		(a)	Representations and Warranties. The representations and warranties made by the Lender in Section 3 hereof shall be true
and correct as of the Closing Date.

 

		(b)	Governmental Approvals and Filings. Except for any notices required or permitted to be filed after the Closing Date
with certain federal and state securities commissions, the Lender shall have obtained all governmental approvals required in connection
with the lawful sale and issuance of the Note.

 

		(c)	Legal Requirements. At the Closing, the sale and issuance by the Company, and the purchase by the Lender, of the Note
shall be legally permitted by all laws and regulations to which the Lender or the Company are subject.

 

		(d)	Purchase Price. The Lender shall have delivered to the Company the principal amount of the Note.

 

		(e)	Approvals. The Company shall have obtained all approvals required in connection with this Agreement and the transactions
contemplated hereby..

 

    6

     

    

		6.	Definitions. As used in this Agreement, the following capitalized terms have the following meanings:

 

“Lien” means,
with respect to any property, any security interest, mortgage, pledge, lien, claim, charge or other encumbrance in, of, or on such
property or the income therefrom, including, without limitation, the interest of a vendor or lessor under a conditional sale agreement,
capital lease or other title retention agreement, or any agreement to provide any of the foregoing, and the filing of any financing
statement or similar instrument under the Uniform Commercial Code or comparable law of any jurisdiction.

 

“Material Adverse Effect”
means a material adverse effect on the ability of the Company to pay or perform the Obligations in accordance with the terms of
the Note and to avoid an Event of Default, or an event which, with the giving of notice or the passage of time or both, would constitute
an Event of Default.

 

“Obligations”
means all loans, advances, debts, liabilities and obligations, howsoever arising, owed by the Company to the Lender under the Note
of every kind and description (whether or not evidenced by any note or instrument and whether or not for the payment of money),
now existing or hereafter arising under or pursuant to the terms of the Note, including all principal, interest, fees, charges,
expenses, attorneys’ fees and costs and accountants’ fees and costs chargeable to and payable by the Company thereunder,
in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or not arising after the commencement
of a proceeding under Title 11 of the United States Code (11 U.S.C. Section 101 et seq.), as amended from time to time (including
post-petition interest) and whether or not allowed or allowable as a claim in any such proceeding.

 

		7.	Miscellaneous.

 

		(a)	Waivers and Amendments. Any provision of this Agreement may be amended, waived or modified only upon the written consent
of the Company and the Lender.

 

		(b)	Governing Law. This Agreement and all actions arising out of or in connection with this Agreement shall be governed
by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the
State of New York or of any other jurisdiction.

 

		(c)	Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement or the Note or the subject
matter hereof or thereof, including, but not limited to, any contractual, pre-contractual or non-contractual rights, obligations
or liabilities and any question or dispute regarding the existence, validity, formation, effect, interpretation, performance, breach,
termination or invalidity hereof or thereof (a “Dispute”), shall be finally settled by arbitration. Any arbitration
initiated in connection with this Section 7(c) shall be conducted by the New York office of the American Arbitration Association
(“AAA”) in accordance with AAA Commercial Rules in effect
at the time of applying for arbitration (“AAA Rules”), except as the AAA Rules conflict with the provisions
of this Section 7(c), in which event the provisions of this Section 7(c) shall control. The arbitration tribunal shall consist
of three (3) arbitrators, one (1) to be appointed by the claimant, one (1) to be appointed by the respondent and the two (2) arbitrators
so appointed shall jointly appoint the third arbitrator. The tribunal shall decide any dispute submitted by the Parties strictly
in accordance with the substantive law of the State of New York and shall not apply any other substantive law. Subject to the agreement
of the tribunal, any Dispute(s) which arise subsequent to the commencement of arbitration of any existing Dispute(s) shall be resolved
by the tribunal already appointed to hear the existing Dispute(s). The arbitration award shall be final, conclusive and binding
on each party as from the date rendered. Judgment upon any arbitration award may be entered and enforced in any court having jurisdiction
over a party or any of its assets.

 

 

    7

     

    

		(d)	Survival. The representations, warranties, covenants and agreements made herein shall survive the execution and delivery
of this Agreement.

 

		(e)	Successors and Assigns. Subject to the restrictions on transfer described in Sections 7(f) and 7(g) below, the rights
and obligations of the Company and the Lender hereunder and under the Note shall be binding upon and inure to the benefit of the
successors, assigns, heirs, administrators and transferees of the Parties.

 

		(f)	Registration, Transfer and Replacement of the Note. The Note issuable under this Agreement shall be issued in registered
form. The Company will keep, at its principal executive office, books for the registration and registration of transfer of the
Note. Prior to presentation of the Note for registration of transfer, the Company shall treat the Person in whose name the Note
is registered as the owner and holder of the Note for all purposes whatsoever, whether or not the Note shall be overdue, and the
Company shall not be affected by notice to the contrary. Subject to any restrictions on or conditions to transfer set forth in
the Note, the holder of the Note, at its option, may in person or by duly authorized attorney surrender the same for exchange at
the Company’s chief executive office, and promptly thereafter and at the Company’s expense, except as provided below,
receive in exchange therefor one or more new Note(s), each in the principal requested by such holder, dated the date to which interest
shall have been paid on the Note so surrendered or, if no interest shall have yet been so paid, dated the date of the Note so surrendered
and registered in the name of such Person or Persons as shall have been designated in writing by such holder or its attorney for
the same principal amount as the then unpaid principal amount of the Note so surrendered. Upon receipt by the Company of evidence
reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of the Note and (a) in the case
of loss, theft or destruction, of indemnity reasonably satisfactory to it; or (b) in the case of mutilation, upon surrender thereof,
the Company, at its expense, will execute and deliver in lieu thereof a new Note executed in the same manner as the Note being
replaced, in the same principal amount as the unpaid principal amount of the Note and dated
the date to which interest shall have been paid on the Note or, if no interest shall have yet been so paid, dated the date of the
Note.

 

 

    8

     

    

		(g)	Assignment by the Company; Assignment by the Lender. Neither this Agreement nor the Note nor any of the rights, interests
or obligations hereunder or thereunder may be assigned, by operation of law or otherwise, in whole or in part, by the Company without
the prior written consent of the Lender. The Lender will not assign, by operation of law or otherwise, this Agreement or the Note
or any of its rights, interests or obligations hereunder or thereunder without the prior written consent of the Company, except
to an Affiliate of the Lender.

 

		(h)	Entire Agreement. This Agreement together with the Note constitute the full and entire understanding and agreement and
supersedes any previous written or verbal agreements between the Parties with regard to the subject matter hereof and thereof.

 

		(i)	Notices. Any notice, request or other communication required or permitted hereunder shall be in writing and shall be
deemed to have been duly given if delivered personally or by commercial delivery service, or sent via telecopy (receipt confirmed)
to the Parties at the following addresses or telecopy numbers (or at such other address or telecopy numbers for a party as shall
be specified by like notice):

 

If to the Company, to:

 

Amyris, Inc.

5885 Hollis St., Ste. 100

Emeryville, CA 94608

Attention: General Counsel

Telecopy No.:

 

with a copy to:

 

Shearman & Sterling LLP

535 Mission St., 25th Floor

San Francisco, CA 94105

Attention:

Telecopy No.:

 

If to the Lender, to:

 

DSM  Finance BV

Het Overloon 1

6411 TE Heerlen

the Netherlands

Attention: General Counsel

with a copy to:

 

Latham & Watkins, LLP

330 North Wabash Avenue, Suite 2800

Chicago, Illinois 60611

Telecopy No.:

Attention:

 

    9

     

    

		(j)	Severability of this Agreement. If any provision of this Agreement shall be judicially determined to be invalid, illegal
or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired
thereby.

 

		(k)	Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but
all of which together shall be deemed to constitute one instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

 

    10

     

    

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to
be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

COMPANY:

 

AMYRIS, INC.

 

By: /s/ John Melo

Name:John Melo

Title:President and Chief Executive Officer

 

LENDER:

 

DSM  FINANCE BV

 

	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 

 

 

 

 

[Credit Agreement Signature Page]

    

     

    

 

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to
be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

COMPANY:

 

AMYRIS, INC.

 

By:   _________________  

Name:John Melo

Title:President and Chief Executive Officer

 

LENDER:

 

DSM  FINANCE BV

 

By: /s/ Bruno Muller

Name: Bruno Muller

Title: Proxy-Holder

 

 

[Credit Agreement Signature Page]

 

    

     

    

 

 

DISCLOSURE SCHEDULE

 

TO THE

 

CREDIT AGREEMENT

 

 

 

Between

 

AMYRIS, INC.

 

and

 

DSM FINANCE BV

 

Dated as of December 28,
2017

 

 

    

     

    

This Disclosure Schedule (this “Disclosure
Schedule”) has been prepared and delivered in connection with the Credit Agreement (the “Agreement”),
dated as of December 28, 2017, between Amyris, Inc., a Delaware corporation, (the “Company”) to DSM Finance
BV, a Netherlands private company with limited liability (the “Lender”). Capitalized terms used herein and not
otherwise defined shall have the meanings set forth in the Agreement.

 

Section references are to Sections of the
Agreement, unless otherwise specified. The headings in this Disclosure Schedule are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Disclosure Schedule.

 

The information provided in this Disclosure
Schedule is being provided solely for the purpose of making disclosures to the Lender under the Agreement. In disclosing this information,
the Company expressly does not waive any attorney-client privilege associated with such information or any protection afforded
by the work-product doctrine with respect to any of the matters disclosed herein.

 

Certain items and matters are listed in
this Disclosure Schedule for informational purposes only and may not be required to be listed therein by the terms of the Agreement.
In no event shall the listing of items or matters in this Disclosure Schedule be deemed or interpreted to broaden, or otherwise
expand the scope of, the representations and warranties or covenants contained in the Agreement. The mere inclusion of an item
in this Disclosure Schedule as an exception to a warranty (x) shall not be deemed an admission that such item represents a material
exception or material event, circumstance, change, effect, development or condition or that such item would constitute a Material
Adverse Effect and (y) shall not be construed as an admission by the Company of any non-compliance with, or violation of, any third-party
rights (including any intellectual property rights) or any law or governmental order. No reference to, or disclosure of, any item
or matter in any Section of this Disclosure Schedule shall be construed as an admission or indication that such item or matter
is material or that such item or matter is required to be referred to or disclosed in this Disclosure Schedule. Without limiting
the foregoing, no reference to or disclosure of a possible breach or violation of any contract, law or governmental order shall
be construed as an admission or indication that a breach or violation exists or has actually occurred.

 

    

     

    

 

Section 2(n)

 

Solvency 

 

With respect to subparagraph (i) of the definition of “Insolvent”
under Section 2(n), the Company notes that it has not performed a valuation to determine the fair saleable value of its assets;
however, the Company notes that its total indebtedness and its total liabilities as reflected in its unaudited balance sheet included
in its Form 10-Q for the quarter ended September 30, 2017 exceed its total assets as reflected in such balance sheet. With respect
to subparagraphs (ii), (iii) and (iv) of the definition of “Insolvent” under Section 2(n), reference is made to the
SEC Documents, including without limitation the disclosures relating to the liquidity of the Company contained in “Notes
to Unaudited Condensed Consolidated Financial Statements—Note 1. The Company—Liquidity,” “Management’s
Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources,” “Risk
Factors—We have incurred losses to date, anticipate continuing to incur losses in the future, and may never achieve or sustain
profitability” and “Risk Factors— We will require significant inflows of cash from product sales and collaborations
and, if needed, financings to fund our anticipated operations and to service our debt obligations and may not be able to obtain
such funding on favorable terms, if at all.”

 

    

     

    

EXHIBIT A

 

FORM OF NOTE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]